Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2019 | Apr. 30, 2019 | |
Document And Entity Information [Abstract] | ||
Entity Registrant Name | Gilead Sciences Inc | |
Entity Central Index Key | 0000882095 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Large Accelerated Filer | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false | |
Entity Emerging Growth Company | false | |
Entity Small Business Company | false | |
Entity Common Stock, Shares Outstanding | 1,271,554,672 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Current assets: | ||
Cash and cash equivalents | $ 16,927 | $ 17,940 |
Short-term marketable securities | 10,977 | 12,149 |
Accounts receivable, net of allowances of $669 and $583, respectively | 3,283 | 3,327 |
Inventories | 898 | 814 |
Prepaid and other current assets | 1,939 | 1,606 |
Total current assets | 34,024 | 35,836 |
Property, plant and equipment, net | 4,116 | 4,006 |
Long-term marketable securities | 2,221 | 1,423 |
Intangible assets, net | 15,438 | 15,738 |
Goodwill | 4,117 | 4,117 |
Other long-term assets | 2,921 | 2,555 |
Total assets | 62,837 | 63,675 |
Current liabilities: | ||
Accounts payable | 577 | 790 |
Accrued government and other rebates | 3,974 | 3,928 |
Other accrued liabilities | 2,348 | 3,139 |
Current portion of long-term debt and other obligations, net | 2,498 | 2,748 |
Total current liabilities | 9,397 | 10,605 |
Long-term debt, net | 24,080 | 24,574 |
Long-term income taxes payable | 5,809 | 5,922 |
Other long-term obligations | 1,460 | 1,040 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding | 0 | 0 |
Common stock, par value $0.001 per share; 5,600 shares authorized; 1,274 and 1,282 shares issued and outstanding, respectively | 1 | 1 |
Additional paid-in capital | 2,494 | 2,282 |
Accumulated other comprehensive income | 130 | 80 |
Retained earnings | 19,326 | 19,024 |
Total Gilead stockholders’ equity | 21,951 | 21,387 |
Noncontrolling interest | 140 | 147 |
Total stockholders’ equity | 22,091 | 21,534 |
Total liabilities and stockholders’ equity | $ 62,837 | $ 63,675 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Statement of Financial Position [Abstract] | ||
Allowance for accounts receivable and chargebacks | $ 669 | $ 583 |
Preferred Stock, Par Value (usd per share) | $ 0.001 | $ 0.001 |
Preferred Stock, Authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred Stock Outstanding (in shares) | 0 | 0 |
Common Stock Par Value (usd per share) | $ 0.001 | $ 0.001 |
Common Stock Authorized (in shares) | 5,600,000,000 | 5,600,000,000 |
Common Stock Issued (in shares) | 1,274,000,000 | 1,282,000,000 |
Common Stock Outstanding (in shares) | 1,274,000,000 | 1,282,000,000 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Revenues: | ||
Revenues | $ 5,281 | $ 5,088 |
Costs and expenses: | ||
Cost of goods sold | 957 | 1,001 |
Research and development expenses | 1,057 | 937 |
Selling, general and administrative expenses | 1,030 | 997 |
Total costs and expenses | 3,044 | 2,935 |
Income from operations | 2,237 | 2,153 |
Interest expense | (254) | (290) |
Other income (expense), net | 367 | 170 |
Income before provision for income taxes | 2,350 | 2,033 |
Provision for income taxes | 382 | 494 |
Net income | 1,968 | 1,539 |
Net income (loss) attributable to noncontrolling interest | (7) | 1 |
Net income attributable to Gilead | $ 1,975 | $ 1,538 |
Net income per share attributable to Gilead common stockholders - basic (usd per share) | $ 1.55 | $ 1.18 |
Shares used in per share calculation - basic (in shares) | 1,276 | 1,307 |
Net income per share attributable to Gilead common stockholders - diluted (usd per share) | $ 1.54 | $ 1.17 |
Shares used in per share calculation - diluted (in shares) | 1,283 | 1,320 |
Product sales | ||
Revenues: | ||
Revenues | $ 5,200 | $ 5,001 |
Royalty, contract and other revenues | ||
Revenues: | ||
Revenues | $ 81 | $ 87 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Statement of Comprehensive Income [Abstract] | ||
Net income | $ 1,968 | $ 1,539 |
Other comprehensive income (loss): | ||
Net foreign currency translation gain, net of tax | 21 | 7 |
Available-for-sale debt securities: | ||
Net unrealized gain (loss), net of tax | 30 | (36) |
Reclassifications to net income, net of tax | 0 | 0 |
Net change | 30 | (36) |
Cash flow hedges: | ||
Net unrealized gain (loss), net of tax | 28 | (61) |
Reclassifications to net income, net of tax | (29) | 48 |
Net change | (1) | (13) |
Other comprehensive income (loss) | 50 | (42) |
Comprehensive income | 2,018 | 1,497 |
Comprehensive income (loss) attributable to noncontrolling interest | (7) | 1 |
Comprehensive income attributable to Gilead | $ 2,025 | $ 1,496 |
Condensed Statements of Stockho
Condensed Statements of Stockholders' Equity - USD ($) shares in Millions, $ in Millions | Total | Common Stock [Member] | Additional Paid-in Capital [Member] | AOCI Attributable to Parent | Retained Earnings [Member] | Noncontrolling Interest [Member] |
Beginning period (in shares) at Dec. 31, 2017 | 1,308 | |||||
Beginning Balance at Dec. 31, 2017 | $ 20,501 | $ 1 | $ 1,264 | $ 165 | $ 19,012 | $ 59 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net income | 1,539 | 1,538 | 1 | |||
Other comprehensive income, net of tax | (42) | (42) | ||||
Issuances under employee stock purchase plan, Shares | 1 | |||||
Issuances under employee stock purchase plan | 48 | 48 | ||||
Issuance under equity incentive plans, Shares | 5 | |||||
Issuances under equity incentive plans | 64 | 64 | ||||
Stock-based compensation | 224 | 224 | ||||
Repurchases of common stock, shares | (14) | |||||
Repurchases of common stock | (1,121) | (36) | (1,085) | |||
Dividends declared | (752) | (752) | ||||
Ending period (in shares) at Mar. 31, 2018 | 1,300 | |||||
Ending Balance at Mar. 31, 2018 | $ 20,651 | $ 1 | 1,564 | (170) | 19,196 | 60 |
Beginning period (in shares) at Dec. 31, 2018 | 1,282 | 1,282 | ||||
Beginning Balance at Dec. 31, 2018 | $ 21,534 | $ 1 | 2,282 | 80 | 19,024 | 147 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Net income | 1,968 | 1,975 | (7) | |||
Other comprehensive income, net of tax | 50 | 50 | ||||
Issuances under employee stock purchase plan, Shares | 1 | |||||
Issuances under employee stock purchase plan | 63 | 63 | ||||
Issuance under equity incentive plans, Shares | 4 | |||||
Issuances under equity incentive plans | 41 | 41 | ||||
Stock-based compensation | 144 | 144 | ||||
Repurchases of common stock, shares | (13) | |||||
Repurchases of common stock | (903) | (36) | (867) | |||
Dividends declared | $ (814) | (814) | ||||
Ending period (in shares) at Mar. 31, 2019 | 1,274 | 1,274 | ||||
Ending Balance at Mar. 31, 2019 | $ 22,091 | $ 1 | $ 2,494 | $ 130 | $ 19,326 | $ 140 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Statement of Stockholders' Equity [Abstract] | ||
Common Stock, Dividends, Per Share, Declared | $ 0.63 | $ 0.57 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Operating Activities: | ||
Net income | $ 1,968 | $ 1,539 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Depreciation expense | 60 | 56 |
Amortization expense | 299 | 301 |
Stock-based compensation expense | 143 | 220 |
Deferred income taxes | 24 | 35 |
Other | (157) | 49 |
Changes in operating assets and liabilities: | ||
Accounts receivable, net | 32 | 101 |
Inventories | (15) | (14) |
Prepaid expenses and other | (43) | 529 |
Accounts payable | (201) | (92) |
Income taxes payable | (249) | (618) |
Accrued liabilities and other | (417) | 164 |
Net cash provided by operating activities | 1,444 | 2,270 |
Investing Activities: | ||
Purchases of marketable debt securities | (6,722) | (397) |
Proceeds from sales of marketable debt securities | 575 | 221 |
Proceeds from maturities of marketable debt securities | 6,511 | 4,762 |
Capital expenditures | (237) | (212) |
Other | 238 | 20 |
Net cash provided by (used in) investing activities | (111) | 4,354 |
Financing Activities: | ||
Proceeds from issuances of common stock | 103 | 111 |
Repurchases of common stock | (834) | (1,039) |
Repayments of debt and other obligations | (750) | (4,500) |
Payments of dividends | (817) | (753) |
Other | (68) | (414) |
Net cash used in financing activities | (2,366) | (6,595) |
Effect of exchange rate changes on cash and cash equivalents | 20 | 26 |
Net change in cash and cash equivalents | (1,013) | 55 |
Cash and cash equivalents at beginning of period | 17,940 | 7,588 |
Cash and cash equivalents at end of period | $ 16,927 | $ 7,643 |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2019 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The financial statements include all adjustments, consisting of normal recurring adjustments that the management of Gilead Sciences, Inc. (Gilead, we, our or us) believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period. The accompanying Condensed Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our Condensed Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. We assess whether we are the primary beneficiary of a variable interest entity (VIE) at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. As of March 31, 2019 , we did not have any material VIEs. The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December 31, 2018 , included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC). Significant Accounting Policies, Estimates and Judgments The preparation of these Condensed Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Actual results may differ significantly from these estimates. Concentrations of Risk We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. We are also subject to credit risk from our accounts receivable related to our product sales. The majority of our trade accounts receivable arises from product sales in the United States and Europe. To date, we have not experienced significant losses with respect to the collection of our accounts receivable. We believe that our allowance for doubtful accounts was adequate as of March 31, 2019 . Recently Adopted Accounting Standards In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2016-02 “Leases” (ASU 2016-02) and subsequently issued supplemental adoption guidance and clarification (collectively, Topic 842). Topic 842 amends a number of aspects of lease accounting, including requiring lessees to recognize right-of-use assets and lease liabilities for operating leases with a lease term greater than one year. Topic 842 supersedes Topic 840 “Leases.” On January 1, 2019, we adopted Topic 842 using the modified retrospective approach. Results for reporting periods beginning after January 1, 2019 are presented under Topic 842, while prior period amounts are not adjusted and continue to be reported in accordance with our historical accounting under Topic 840. We elected the package of practical expedients permitted under the transition guidance within Topic 842, which allowed us to carry forward the historical lease classification, retain the initial direct costs for any leases that existed prior to the adoption of the standard and not reassess whether any contracts entered into prior to the adoption are leases. We also elected to account for lease and nonlease components in our lease agreements as a single lease component in determining lease assets and liabilities. In addition, we elected not to recognize the right-of-use assets and liabilities for leases with lease terms of one year or less. Upon adoption of Topic 842, we recorded $441 million of right-of-use assets within Other long-term assets and $ 490 million of operating lease liabilities, classified primarily within Other long-term obligations on our Condensed Consolidated Balance Sheet, as of January 1, 2019. The adoption did not have a material impact on our Condensed Consolidated Statements of Income or Condensed Consolidated Statements of Cash Flows. See Note 10 . Leases for additional information. Recently Issued Accounting Standards Not Yet Adopted In June 2016, the FASB issued Accounting Standards Update No. 2016-13 “Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments” (ASU 2016-13). ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within ASU 2019-04 “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments.” The guidance will become effective for us beginning in the first quarter of 2020 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted beginning in the first quarter of 2019. We are evaluating the impact of the adoption of these standards but we currently do not expect a material impact on our Condensed Consolidated Financial Statements. In November 2018, the FASB issued Accounting Standards Update No. 2018-18 “Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606” (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. This guidance will become effective for us beginning in the first quarter of 2020 and will be applied retrospectively to January 1, 2018 when we initially adopted Topic 606. Early adoption is permitted. We are evaluating the impact of the adoption of this standard but we currently do not expect a material impact on our revenue. |
Revenues
Revenues | 3 Months Ended |
Mar. 31, 2019 | |
Revenue from Contract with Customer [Abstract] | |
Revenues | REVENUES Disaggregation of Revenues The following table disaggregates our product sales by product and geographic region and disaggregates our royalty, contract and other revenues by geographic region (in millions): Three Months Ended March 31, 2019 Three Months Ended March 31, 2018 U.S. Europe Other International Total U.S. Europe Other International Total Product sales: Atripla $ 133 $ 16 $ 22 $ 171 $ 228 $ 51 $ 35 $ 314 Biktarvy 739 48 6 793 35 — — 35 Complera/Eviplera 44 62 9 115 67 109 14 190 Descovy 233 68 41 342 274 75 12 361 Genvoya 728 193 94 1,015 853 186 43 1,082 Odefsey 282 106 9 397 279 58 5 342 Stribild 67 18 11 96 133 29 12 174 Truvada 551 33 22 606 507 97 48 652 Other HIV (1) 11 1 5 17 9 1 3 13 Revenue share – Symtuza (2) 42 24 — 66 — 7 — 7 AmBisome 8 57 28 93 17 56 34 107 Ledipasvir/Sofosbuvir (3) 117 27 81 225 234 56 58 348 Letairis 197 — — 197 204 — — 204 Ranexa 155 — — 155 195 — — 195 Sofosbuvir/Velpatasvir (4) 230 154 107 491 269 198 69 536 Vemlidy 65 4 32 101 47 3 8 58 Viread 12 14 46 72 7 30 60 97 Vosevi 45 16 2 63 86 16 5 107 Yescarta 90 6 — 96 40 — — 40 Zydelig 11 15 1 27 14 18 1 33 Other (5) 36 20 6 62 29 15 62 106 Total product sales 3,796 882 522 5,200 3,527 1,005 469 5,001 Royalty, contract and other revenues 22 56 3 81 20 52 15 87 Total revenues $ 3,818 $ 938 $ 525 $ 5,281 $ 3,547 $ 1,057 $ 484 $ 5,088 ____________________ Notes: (1) Includes Emtriva and Tybost (2) Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland UC (Janssen) (3) Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC (4) Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC (5) Includes Cayston, Hepsera and Sovaldi Revenues Recognized from Performance Obligations Satisfied in Prior Periods During the three months ended March 31, 2019 and 2018 , revenues recognized from performance obligations satisfied in prior years related to royalties for licenses of our intellectual property were $155 million and $97 million , respectively. Changes in estimates for variable consideration related to sales made in prior years resulted in a $107 million increase and $87 million decrease in revenues during the three months ended March 31, 2019 and 2018 , respectively. Contract Balances Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $140 million and $125 million as of March 31, 2019 and December 31, 2018 , respectively. Contract liabilities were not material as of March 31, 2019 and December 31, 2018 . |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Mar. 31, 2019 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | FAIR VALUE MEASUREMENTS We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows: • Level 1 inputs include quoted prices in active markets for identical assets or liabilities; • Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. For our marketable securities, we review trading activity and pricing as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data; and • Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities and foreign currency exchange contracts are reported at their respective fair values on our Condensed Consolidated Balance Sheets. Equity securities with no readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs on our Condensed Consolidated Balance Sheets. The remaining financial instruments are reported in our Condensed Consolidated Balance Sheets at amounts that approximate current fair values. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented. The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in millions): March 31, 2019 December 31, 2018 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Available-for-sale debt securities: U.S. treasury securities $ 4,782 $ — $ — $ 4,782 $ 3,969 $ — $ — $ 3,969 Certificates of deposit — 4,211 — 4,211 — 4,361 — 4,361 U.S. government agencies securities — 1,444 — 1,444 — 938 — 938 Municipal debt securities — 25 — 25 — — — — Non-U.S. government securities — 452 — 452 — 305 — 305 Corporate debt securities — 12,565 — 12,565 — 13,067 — 13,067 Residential mortgage and asset-backed securities — 1,036 — 1,036 — 1,524 — 1,524 Equity securities: Money market funds 3,778 — — 3,778 5,305 — — 5,305 Publicly traded equity securities 1,099 18 — 1,117 881 — — 881 Deferred compensation plan 150 — 150 124 — — 124 Foreign currency derivative contracts — 77 — 77 — 78 — 78 Total $ 9,809 $ 19,828 $ — $ 29,637 $ 10,279 $ 20,273 $ — $ 30,552 Liabilities: Deferred compensation plan $ 150 $ — $ — $ 150 $ 124 $ — $ — $ 124 Foreign currency derivative contracts — 2 — 2 — 1 — 1 Total $ 150 $ 2 $ — $ 152 $ 124 $ 1 $ — $ 125 For the three months ended March 31, 2019 and 2018 , changes in the fair value of equity securities resulted in net unrealized gains of $197 million and $45 million , respectively, which were included in Other income (expense), net on our Condensed Consolidated Statements of Income. Investments in equity securities without readily determinable fair values were not material for the periods presented. The following table summarizes the classification of our equity securities in our Condensed Consolidated Balance Sheets (in millions): March 31, 2019 December 31, 2018 Cash and cash equivalents $ 3,778 $ 5,305 Prepaid and other current assets 1,105 863 Other long-term assets 162 142 Total $ 5,045 $ 6,310 Our available-for-sale debt securities are classified as cash equivalents, short-term marketable securities and long-term marketable securities on our Condensed Consolidated Balance Sheets. See Note 4 . Available-for-Sale Debt Securities for additional information. Level 2 Inputs We estimate the fair values of Level 2 instruments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&P Global Ratings, Moody’s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, London Interbank Offered Rates (LIBOR) and swap rates. These inputs, where applicable, are observable at commonly quoted intervals. The total estimated fair values of our short-term and long-term debt, determined using Level 2 inputs based on their quoted market values, were approximately $27.3 billion and $27.1 billion as of March 31, 2019 and December 31, 2018 , respectively, and the carrying values were $26.6 billion and $27.3 billion as of March 31, 2019 and December 31, 2018 , respectively. |
Available-for-Sale Debt Securit
Available-for-Sale Debt Securities | 3 Months Ended |
Mar. 31, 2019 | |
Debt Securities, Available-for-sale [Abstract] | |
Available-for-Sale Debt Securities | AVAILABLE-FOR-SALE DEBT SECURITIES The following table summarizes our available-for-sale debt securities (in millions): March 31, 2019 December 31, 2018 Amortized Gross Gross Estimated Amortized Gross Gross Estimated U.S. treasury securities $ 4,786 $ — $ (4 ) $ 4,782 $ 3,978 $ — $ (9 ) $ 3,969 Certificates of deposit 4,211 — — 4,211 4,361 — — 4,361 U.S. government agencies securities 1,446 — (2 ) 1,444 943 — (5 ) 938 Municipal debt securities 25 — — 25 — — — — Non-U.S. government securities 453 — (1 ) 452 307 — (2 ) 305 Corporate debt securities 12,576 1 (12 ) 12,565 13,095 1 (29 ) 13,067 Residential mortgage and asset-backed securities 1,040 — (4 ) 1,036 1,532 — (8 ) 1,524 Total $ 24,537 $ 1 $ (23 ) $ 24,515 $ 24,216 $ 1 $ (53 ) $ 24,164 The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets (in millions): March 31, 2019 December 31, 2018 Cash and cash equivalents $ 11,317 $ 10,592 Short-term marketable securities 10,977 12,149 Long-term marketable securities 2,221 1,423 Total $ 24,515 $ 24,164 The following table summarizes our available-for-sale debt securities by contractual maturity (in millions): March 31, 2019 Amortized Cost Fair Value Within one year $ 22,313 $ 22,294 After one year through five years 2,175 2,172 After five years through ten years 31 31 After ten years 18 18 Total $ 24,537 $ 24,515 The following table summarizes our available-for-sale debt securities that were in a continuous unrealized loss position, but were not deemed to be other-than-temporarily impaired (in millions): Less Than 12 Months 12 Months or Greater Total Gross Estimated Gross Estimated Gross Estimated March 31, 2019 U.S. treasury securities $ — $ 2,971 $ (4 ) $ 917 $ (4 ) $ 3,888 U.S. government agencies securities — 483 (2 ) 458 (2 ) 941 Non-U.S. government securities — 100 (1 ) 160 (1 ) 260 Corporate debt securities (1 ) 1,049 (11 ) 2,938 (12 ) 3,987 Residential mortgage and asset-backed securities — 85 (4 ) 817 (4 ) 902 Total $ (1 ) $ 4,688 $ (22 ) $ 5,290 $ (23 ) $ 9,978 December 31, 2018 U.S. treasury securities $ — $ 896 $ (9 ) $ 1,383 $ (9 ) $ 2,279 U.S. government agencies securities — 30 (5 ) 553 (5 ) 583 Non-U.S. government securities — 86 (2 ) 192 (2 ) 278 Corporate debt securities (1 ) 1,600 (28 ) 4,204 (29 ) 5,804 Residential mortgage and asset-backed securities — 192 (8 ) 1,186 (8 ) 1,378 Total $ (1 ) $ 2,804 $ (52 ) $ 7,518 $ (53 ) $ 10,322 We held a total of 915 and 1,348 positions, which were in an unrealized loss position, as of March 31, 2019 and December 31, 2018 , respectively. Based on our review of these securities, we believe we had no other-than-temporary impairments as of March 31, 2019 and December 31, 2018 , because we do not intend to sell these securities nor do we believe that we will be required to sell these securities before the recovery of their amortized cost basis. Gross realized gains and gross realized losses were not material for the three months ended March 31, 2019 and 2018 . |
Derivative Financial Instrument
Derivative Financial Instruments | 3 Months Ended |
Mar. 31, 2019 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Financial Instruments | DERIVATIVE FINANCIAL INSTRUMENTS Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we may hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward or option contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrecognized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes. We hedge our exposure to foreign currency exchange rate fluctuations for certain monetary assets and liabilities of our entities that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are not designated as hedges and, as a result, changes in their fair value are recorded in Other income (expense), net on our Condensed Consolidated Statements of Income. We hedge our exposure to foreign currency exchange rate fluctuations for forecasted product sales that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are designated as cash flow hedges and have maturities of 18 months or less. Upon executing a hedging contract and quarterly thereafter, we assess hedge effectiveness using regression analysis. The unrealized gains or losses in Accumulated other comprehensive income ( AOCI) are reclassified into product sales when the respective hedged transactions affect earnings. The majority of gains and losses related to the hedged forecasted transactions reported in AOCI at March 31, 2019 are expected to be reclassified to product sales within 12 months . The cash flow effects of our derivative contracts for the three months ended March 31, 2019 and 2018 were included within Net cash provided by operating activities on our Condensed Consolidated Statements of Cash Flows. We had notional amounts on foreign currency exchange contracts outstanding of $2.5 billion and $2.2 billion at March 31, 2019 and December 31, 2018 , respectively. While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts on a gross basis. The following table summarizes the classification and fair values of derivative instruments in our Condensed Consolidated Balance Sheets (in millions): March 31, 2019 Asset Derivatives Liability Derivatives Classification Fair Value Classification Fair Value Derivatives designated as hedges: Foreign currency exchange contracts Other current assets $ 74 Other accrued liabilities $ (1 ) Foreign currency exchange contracts Other long-term assets 3 Other long-term obligations — Total derivatives designated as hedges 77 (1 ) Derivatives not designated as hedges: Foreign currency exchange contracts Other current assets — Other accrued liabilities (1 ) Total derivatives not designated as hedges — (1 ) Total derivatives $ 77 $ (2 ) December 31, 2018 Asset Derivatives Liability Derivatives Classification Fair Value Classification Fair Value Derivatives designated as hedges: Foreign currency exchange contracts Other current assets $ 73 Other accrued liabilities $ (1 ) Foreign currency exchange contracts Other long-term assets 5 Other long-term obligations — Total derivatives designated as hedges 78 (1 ) Derivatives not designated as hedges: Foreign currency exchange contracts Other current assets — Other accrued liabilities — Total derivatives not designated as hedges — — Total derivatives $ 78 $ (1 ) The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements (in millions): Three Months Ended March 31, 2019 2018 Derivatives designated as hedges: Gains (losses) recognized in AOCI $ 28 $ (61 ) Gains (losses) reclassified from AOCI into product sales 29 (48 ) Derivatives not designated as hedges: Losses recognized in Other income (expense), net $ (6 ) $ (14 ) From time to time, we may discontinue cash flow hedges and, as a result, record related amounts in Other income (expense), net on our Condensed Consolidated Statements of Income. There were no material amounts recorded in Other income (expense), net on our Condensed Consolidated Statements of Income for the three months ended March 31, 2019 and 2018 as a result of the discontinuance of cash flow hedges. As of March 31, 2019 and December 31, 2018 , we only held foreign currency exchange contracts. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument on our Condensed Consolidated Balance Sheets (in millions): Gross Amounts Not Offset on our Condensed Consolidated Balance Sheets Description Gross Amounts of Recognized Assets/Liabilities Gross Amounts Offset on our Condensed Consolidated Balance Sheets Amounts of Assets/Liabilities Presented on our Condensed Consolidated Balance Sheets Derivative Financial Instruments Cash Collateral Received/ Pledged Net Amount (Legal Offset) As of March 31, 2019 Derivative assets $ 77 $ — $ 77 $ (2 ) $ — $ 75 Derivative liabilities (2 ) — (2 ) 2 — — As of December 31, 2018 Derivative assets $ 78 $ — $ 78 $ (1 ) $ — $ 77 Derivative liabilities (1 ) — (1 ) 1 — — |
Collaborative Arrangements
Collaborative Arrangements | 3 Months Ended |
Mar. 31, 2019 | |
Collaborative Arrangements [Abstract] | |
Collaborative Arrangement Disclosure | COLLABORATIVE ARRANGEMENTS We enter into collaborative arrangements with third parties for the development and commercialization of certain products and product candidates. These arrangements involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable up-front payments, payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements, cost-sharing arrangements, equity investments, or a combination of these terms. During the three months ended March 31, 2019 , we entered into collaboration arrangements that resulted in cash payments of $165 million , of which $126 million was recorded as up-front collaboration expense within Research and development expenses on our Condensed Consolidated Statements of Income and the remaining balance was recorded in Prepaid and other current assets on our Condensed Consolidated Balance Sheets. During the three months ended March 31, 2018 , the initial cash consideration related to collaborations and other arrangements was not material. We do not consider any of these collaboration arrangements to be individually material. Under the financial terms of these arrangements, we may be required to make payments upon achievement of various developmental, regulatory and commercial milestones, which could be significant. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurrence. Future milestone payments and royalties, if any, will be reflected on our Condensed Consolidated Statements of Income when the corresponding events become probable. |
Other Financial Information
Other Financial Information | 3 Months Ended |
Mar. 31, 2019 | |
Other Financial Information [Abstract] | |
Other Financial Information | OTHER FINANCIAL INFORMATION Inventories The following table summarizes our inventories (in millions): March 31, 2019 December 31, 2018 Raw materials $ 1,860 $ 1,888 Work in process 267 235 Finished goods 501 507 Total $ 2,628 $ 2,630 Reported as: Inventories $ 898 $ 814 Other long-term assets 1,730 1,816 Total $ 2,628 $ 2,630 Amounts reported as other long-term assets primarily consisted of raw materials as of March 31, 2019 and December 31, 2018 . Other Accrued Liabilities The following table summarizes the components of other accrued liabilities (in millions): March 31, 2019 December 31, 2018 Compensation and employee benefits $ 325 $ 555 Accrued payment for marketing-related rights acquired from Japan Tobacco Inc. 185 365 Other accrued expenses 1,838 2,219 Total $ 2,348 $ 3,139 |
Intangible Assets
Intangible Assets | 3 Months Ended |
Mar. 31, 2019 | |
Intangible Assets, Net (Excluding Goodwill) [Abstract] | |
Intangible Assets | INTANGIBLE ASSETS The following table summarizes our intangible assets, net (in millions): March 31, 2019 December 31, 2018 Gross Carrying Amount Accumulated Amortization Foreign Currency Translation Adjustment Net Carrying Amount Gross Carrying Amount Accumulated Amortization Foreign Currency Translation Adjustment Net Carrying Amount Finite-lived assets: Intangible asset - sofosbuvir $ 10,720 $ (3,729 ) $ — $ 6,991 $ 10,720 $ (3,554 ) $ — $ 7,166 Intangible asset - axicabtagene ciloleucel (DLBCL) 6,200 (502 ) — 5,698 6,200 (416 ) — 5,784 Intangible asset - Ranexa 688 (688 ) — — 688 (678 ) — 10 Other 1,098 (387 ) (4 ) 707 1,096 (359 ) (3 ) 734 Total finite-lived assets 18,706 (5,306 ) (4 ) 13,396 18,704 (5,007 ) (3 ) 13,694 Indefinite-lived assets - In Process Research & Development 2,047 — (5 ) 2,042 2,047 — (3 ) 2,044 Total intangible assets $ 20,753 $ (5,306 ) $ (9 ) $ 15,438 $ 20,751 $ (5,007 ) $ (6 ) $ 15,738 Aggregate amortization expense related to finite-lived intangible assets was $299 million and $301 million for the three months ended March 31, 2019 and 2018 , respectively, and was primarily included in Cost of goods sold on our Condensed Consolidated Statements of Income. The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March 31, 2019 (in millions): Fiscal Year Amount 2019 (remaining nine months) $ 851 2020 1,125 2021 1,125 2022 1,125 2023 1,125 Thereafter 8,045 Total $ 13,396 |
Debt and Credit Facilities
Debt and Credit Facilities | 3 Months Ended |
Mar. 31, 2019 | |
Debt Disclosure [Abstract] | |
Debt and Credit Facilities | DEBT AND CREDIT FACILITIES The following table summarizes our borrowings under various financing arrangements (in millions): Carrying Amount Type of Borrowing Issue Date Due Date Interest Rate March 31, 2019 December 31, 2018 Senior Unsecured September 2017 March 2019 3-month LIBOR + 0.22% $ — $ 750 Senior Unsecured March 2014 April 2019 2.05% 500 500 Senior Unsecured September 2017 September 2019 1.85% 999 999 Senior Unsecured September 2017 September 2019 3-month LIBOR + 0.25% 500 499 Senior Unsecured November 2014 February 2020 2.35% 499 499 Senior Unsecured September 2015 September 2020 2.55% 1,997 1,996 Senior Unsecured March 2011 April 2021 4.50% 997 997 Senior Unsecured December 2011 December 2021 4.40% 1,247 1,247 Senior Unsecured September 2016 March 2022 1.95% 498 498 Senior Unsecured September 2015 September 2022 3.25% 997 997 Senior Unsecured September 2016 September 2023 2.50% 746 746 Senior Unsecured March 2014 April 2024 3.70% 1,744 1,744 Senior Unsecured November 2014 February 2025 3.50% 1,745 1,745 Senior Unsecured September 2015 March 2026 3.65% 2,732 2,731 Senior Unsecured September 2016 March 2027 2.95% 1,245 1,245 Senior Unsecured September 2015 September 2035 4.60% 990 990 Senior Unsecured September 2016 September 2036 4.00% 740 740 Senior Unsecured December 2011 December 2041 5.65% 995 995 Senior Unsecured March 2014 April 2044 4.80% 1,734 1,734 Senior Unsecured November 2014 February 2045 4.50% 1,731 1,730 Senior Unsecured September 2015 March 2046 4.75% 2,217 2,216 Senior Unsecured September 2016 March 2047 4.15% 1,725 1,724 Total debt, net 26,578 27,322 Less current portion 2,498 2,748 Total long-term debt, net $ 24,080 $ 24,574 In March 2019 , we repaid $750 million of our senior unsecured notes upon maturity that were issued in September 2017 . We are required to comply with certain covenants under our credit agreement and note indentures governing our senior notes. As of March 31, 2019 , we were not in violation of any covenants. Additionally, as of March 31, 2019 and December 31, 2018 , there were no amounts outstanding under our $2.5 billion five -year revolving credit facility agreement maturing in May 2021. In April 2019 , we repaid $500 million of our senior unsecured notes upon maturity that were issued in March 2014 . |
Leases
Leases | 3 Months Ended |
Mar. 31, 2019 | |
Leases [Abstract] | |
Leases | LEASES We lease facilities and equipment primarily related to administrative, research and development, and sales and marketing activities under various non-cancelable operating leases in the United States and international markets. We determine if an arrangement contains a lease at inception. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term, which is the non-cancelable period stated in the contract adjusted for any options to extend or terminate when it is reasonably certain that we will exercise that option. Some of our leases include options to extend the terms for up to 15 years and some include options to terminate the lease within one year after the lease commencement date. Right-of-use assets include any prepaid lease payments, and exclude lease incentives and initial direct costs incurred. As of March 31, 2019 , we do not have material finance leases. As most of our operating leases do not provide an implicit interest rate, we use a portfolio approach to determine a collateralized incremental borrowing rate based on the information available at the commencement date to determine the lease liability. Operating lease expense is recognized on a straight-line basis over the lease term. Operating lease expense was $36 million for the three months ended March 31, 2019 . The following table summarizes balance sheet and other information related to our operating leases as of March 31, 2019 (in millions, except weighted average data): Classification Amount Right-of-use assets, net Other long-term assets $ 455 Lease liabilities - current Other accrued liabilities $ 75 Lease liabilities - noncurrent Other long-term obligations $ 429 Weighted average remaining lease term 9.5 years Weighted average discount rate 3.61 % The following table summarizes other supplemental information related to our operating leases (in millions): Three Months Ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities $ 18 Right-of-use assets obtained in exchange for lease liabilities $ 30 The following table summarizes a maturity analysis of our operating lease liabilities showing the aggregate lease payments as of March 31, 2019 (in millions): Fiscal Year Amount 2019 (remaining nine months) $ 69 2020 84 2021 72 2022 65 2023 57 Thereafter 257 Total undiscounted lease payments 604 Less: imputed interest (100 ) Total discounted lease payments $ 504 The following table summarizes the aggregate undiscounted non-cancelable future minimum lease payments for operating leases under the prior leases standard as of December 31, 2018 (in millions): Fiscal Year Amount 2019 $ 89 2020 78 2021 66 2022 60 2023 52 Thereafter 229 Total minimum lease payments $ 574 |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | COMMITMENTS AND CONTINGENCIES We are a party to various legal actions. The most significant of these are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, it is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss. We did not recognize any accruals for the actions described below in our Condensed Consolidated Balance Sheets as of March 31, 2019 and December 31, 2018 , as we did not believe losses were probable. Litigation Related to Sofosbuvir In January 2012, we acquired Pharmasset, Inc. (Pharmasset). Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of the hepatitis C virus (HCV). In December 2013, we received approval from U.S. Food and Drug Administration (FDA) for sofosbuvir, now known commercially as Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss. We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims. Litigation with Idenix Pharmaceuticals, Inc. (Idenix), Universita Degli Studi di Cagliari (UDSG), Centre National de la Recherche Scientifique and L’Universite Montpellier II In 2013, Idenix, UDSG, Centre National de la Recherche Scientifique and L’Université Montpellier II sued us in U.S. District Court for the District of Delaware alleging that the commercialization of sofosbuvir infringes U.S. Patent No. 7,608,600 (the ‘600 patent). Also in 2013, Idenix and UDSG sued us in the U.S. District Court for the District of Massachusetts alleging that the commercialization of sofosbuvir infringes U.S. Patent Nos. 6,914,054 (the ‘054 patent) and 7,608,597 (the ‘597 patent). In 2014, the court transferred the Massachusetts litigation to the U.S. District Court for the District of Delaware. Prior to trial in 2016, Idenix committed to give us a covenant not to sue with respect to any claims arising out of the ‘054 patent related to sofosbuvir and withdrew that patent from the trial. A jury trial was held in 2016 on the ‘597 patent, and the jury found that we willfully infringed the asserted claims of the ‘597 patent and awarded Idenix $2.54 billion in past damages. In 2018, the judge invalidated Idenix’s ‘597 patent and vacated the jury’s award of $2.54 billion in past damages. Idenix appealed this decision to the U.S. Court of Appeals for the Federal Circuit (CAFC), and briefing is now complete. We believe the Delaware court’s decision correctly found that, as a matter of law, the ‘597 patent is invalid, and we remain confident in the merits of our case on appeal. We believe that the possibility of a material adverse outcome on this matter is remote. In 2014, the European Patent Office (EPO) granted Idenix's European Patent No. 1 523 489 (the ‘489 patent), which corresponds to the ‘600 patent. The same day that the ‘489 patent was granted, we filed an opposition with the EPO seeking to revoke the ‘489 patent. An opposition hearing was held in 2016, and the EPO ruled in our favor and revoked the ‘489 patent. Idenix has appealed. In 2014, Idenix also initiated infringement proceedings against us in Germany and France alleging that the commercialization of Sovaldi would infringe the German and French counterparts of the ‘489 patent. In 2015, the German court in Düsseldorf determined that the Idenix patent was highly likely to be invalid and stayed the infringement proceedings pending the outcome of the opposition hearing held by the EPO in 2016. Idenix has not appealed this decision of the German court staying the proceedings. Upon Idenix’s request, the French proceedings have been stayed. Litigation with Merck & Co. Inc. (Merck) In 2013, Merck contacted us requesting that we pay royalties on the sales of sofosbuvir and obtain a license to U.S. Patent No. 7,105,499 (the ‘499 patent) and U.S. Patent No. 8,481,712 (the ‘712 patent), which it co-owns with Ionis Pharmaceuticals, Inc. The ‘499 and ‘712 patents cover compounds which do not include, but may relate to, sofosbuvir. We filed a lawsuit in 2013 in the U.S. District Court for the Northern District of California seeking a declaratory judgment that the Merck patents are invalid and not infringed. Initially, in 2016, a jury determined that we had not established that Merck’s patents are invalid and awarded Merck $200 million in damages. However, in 2016, the court ruled in our favor on our defense of unclean hands and determined that Merck may not recover any damages from us for the ‘499 and ‘712 patents. In 2018, the CAFC affirmed the court’s decision on unclean hands. In January 2019, the U.S. Supreme Court denied Merck’s petition for review. In March 2019, the parties executed an agreement concerning the total amount that Merck should reimburse us for the court’s award of attorney’s fees, appellate fees and interest, and Merck paid us the agreed upon amount. Accordingly, this matter is now closed. Litigation with the University of Minnesota The University of Minnesota (the University) has obtained Patent No. 8,815,830 (the ‘830 patent), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the ‘830 patent. We believe the ‘830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed four petitions for inter partes review with the USPTO Patent Trial and Appeal Board (PTAB) alleging that all asserted claims are invalid for anticipation and obviousness. In 2018, the District Court stayed the litigation until after the PTAB rules on our petitions for inter partes review. Litigation Related to Axicabtagene Ciloleucel We own patents and patent applications that claim axicabtagene ciloleucel chimeric DNA segments. Third parties may have, or may obtain rights to, patents that allegedly could be used to prevent or attempt to prevent us from commercializing axicabtagene ciloleucel or to require us to obtain a license in order to commercialize axicabtagene ciloleucel. For example, we are aware that Juno Therapeutics, Inc. (Juno) has exclusively licensed Patent No. 7,446,190 (the ‘190 patent), which was issued to Sloan Kettering Cancer Center. In September 2017, Juno and Sloan Kettering Cancer Center filed a lawsuit against Kite in the U.S. District Court for the Central District of California, alleging that the commercialization of axicabtagene ciloleucel infringes the ‘190 patent. In October 2017, following FDA approval for Yescarta, Juno filed a second complaint alleging that axicabtagene ciloleucel infringes the ‘190 patent. Juno subsequently moved to dismiss the September 2017 complaint and has maintained the October 2017 complaint. The court has set a trial date of December 2019 for this lawsuit. We cannot predict the ultimate outcome of intellectual property claims related to axicabtagene ciloleucel. If Juno’s patent is upheld as valid and Juno successfully proves infringement of that patent by axicabtagene ciloleucel, we could be required to pay significant monetary damages or we could be prevented from selling Yescarta unless we were able to obtain a license to this patent. Such a license may not be available on commercially reasonable terms or at all. Litigation Related to Bictegravir In 2018, ViiV Healthcare Company (ViiV) filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the commercialization of bictegravir, sold commercially in combination with tenofovir alafenamide and emtricitabine as Biktarvy, infringes ViiV’s U.S. Patent No. 8,129,385 (the ‘385 patent), which was issued to Shionogi & Co. Ltd. and GlaxoSmithKline LLC. The ‘385 patent is the compound patent covering ViiV’s dolutegravir. Bictegravir is structurally different from dolutegravir, and we believe that bictegravir does not infringe the claims of the ‘385 patent. To the extent that ViiV’s patent claims are interpreted to cover bictegravir, we believe those claims are invalid. The U.S. Patent and Trademark Office (USPTO) has granted us patents covering bictegravir. The court has set a trial date of September 2020 for this lawsuit. In 2018, ViiV also filed a lawsuit against us in the Federal Court of Canada, alleging that our activities relating to our bictegravir compound have infringed ViiV’s Canadian Patent No. 2,606,282 (the ‘282 patent), which was issued to Shionogi & Co. Ltd. and ViiV. The ‘282 patent is the compound patent covering ViiV’s dolutegravir. We believe that bictegravir does not infringe the claims of the ‘282 patent. To the extent that ViiV’s patent claims are interpreted to cover bictegravir, we believe those claims are invalid. We cannot predict the ultimate outcome of intellectual property claims related to bictegravir. If ViiV’s patents are upheld as valid and ViiV successfully proves infringement of those patents by bictegravir, we could be required to pay significant monetary damages. Litigation with Generic Manufacturers As part of the approval process for some of our products, FDA granted us a New Chemical Entity (NCE) exclusivity period during which other manufacturers’ applications for approval of generic versions of our product will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (ANDA), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product’s approval. Current legal proceedings of significance with generic manufacturers include: HIV Products In 2018, we received notice that Zydus Pharmaceuticals (USA) Inc. (Zydus) submitted an ANDA to FDA requesting permission to manufacture and market generic versions of Truvada at various dosage strengths. In the notice, Zydus alleges that two patents associated with emtricitabine and four patents associated with the emtricitabine and tenofovir disoproxil fumarate fixed-dose combination are invalid, unenforceable and/or will not be infringed by Zydus’ manufacture, use or sale of generic versions of Truvada at various dosage strengths. In response, we filed a lawsuit against Zydus in the U.S. District Court for the District of New Jersey for infringement of our patents. In 2018, we received notice that Mylan Pharmaceuticals Inc. (Mylan) submitted an ANDA to FDA requesting permission to manufacture and market a generic version of Stribild. In the notice, Mylan alleges that one patent owned by Japan Tobacco Inc. (JT) and associated with elvitegravir is invalid, unenforceable and/or will not be infringed by Mylan’s manufacture, use or sale of a generic version of Stribild. In 2019, JT filed a lawsuit against Mylan in the U.S. District Court for the Northern District of West Virginia for infringement of its patent. HCV Products In 2018, we received notices from Natco Pharma Limited (Natco) and Teva Pharmaceuticals (Teva) that they have each submitted an ANDA to FDA requesting permission to manufacture and market a generic version of Sovaldi. In Teva’s notice, it alleges that nine patents associated with sofosbuvir are invalid, unenforceable and/or will not be infringed by Teva’s manufacture, use or sale of generic versions of Sovaldi. In response, we filed lawsuits against Teva in the U.S. District Court for the District of New Jersey and the U.S. District Court for the District of Delaware for infringement of these patents. In Natco’s notice, it alleges that two patents associated with sofosbuvir are invalid, unenforceable and/or will not be infringed by Natco’s manufacture, use or sale of generic versions of Sovaldi. Natco did not challenge all patents listed on the Orange Book for Sovaldi. We also filed lawsuits against Natco in the U.S. District Court for the District of New Jersey and the U.S. District Court for the District of Delaware for infringement of these patents. In 2018, we reached an agreement with Teva to resolve the lawsuit, which has been dismissed. The settlement agreement has been filed with the Federal Trade Commission and Department of Justice as required by law. European Patent Claims In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also appealed, requesting full revocation. The appeal process may take several years. In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. Two of the original opposing parties have appealed, requesting full revocation. The appeal process may take several years. In 2016, several parties filed oppositions in the EPO requesting revocation of our granted European patent covering TAF that expires in 2021. In 2017, the EPO upheld the validity of the claims of our TAF patent. Three parties have appealed this decision. The appeal process may take several years. In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. We responded to these oppositions, and a hearing was held in February 2019. The patent was upheld at this hearing. The opposing parties may choose to appeal this decision, which could take several years to conclude. In 2016, three parties filed oppositions in the EPO requesting revocation of our granted European patent covering cobicistat that expires in 2027. In 2017, the EPO upheld the validity of the claims of our cobicistat patent. One of the original opposing parties has appealed this decision. The appeal process may take several years. While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir, TAF and cobicistat in the European Union could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by the European Medicines Agency. If we lose patent protection for any of these compounds, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost, which may cause our stock price to decline. Government Investigations and Related Litigation In 2011, we received a subpoena from the U.S. Attorney’s Office for the Northern District of California requesting documents related to the manufacture, and related quality and distribution practices, of Complera, Atripla, Truvada, Viread, Emtriva, Hepsera and Letairis. We cooperated with the government’s inquiry. In 2014, the U.S. Department of Justice informed us that, following an investigation, it declined to intervene in a False Claims Act lawsuit filed by two former employees. Also in 2014, the former employees served a First Amended Complaint, and the U.S. District Court for the Northern District of California issued an order granting in its entirety, without prejudice, our motion to dismiss the First Amended Complaint. In 2015, the plaintiffs filed a Second Amended Complaint, and the District Court issued an order granting our motion to dismiss the Second Amended Complaint. The plaintiffs then filed a notice of appeal in the U.S. Court of Appeals for the Ninth Circuit. In 2017, the Ninth Circuit granted our motion to stay the case pending an appeal to the U.S. Supreme Court, and we filed a Petition for a Writ of Certiorari to the U.S. Supreme Court. In 2018, the Solicitor General submitted a brief for the United States to the Supreme Court stating its intention to file a motion to dismiss under the federal False Claims Act. In January 2019, the Supreme Court denied the Petition and the case has been remanded to the District Court. In March 2019, the Department of Justice filed a motion to dismiss the Second Amended Complaint, which the District Court is expected to rule upon later this year. In 2016, we received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts requesting documents related to our support of 501(c)(3) organizations that provide financial assistance to patients and documents concerning our provision of financial assistance to patients for our HCV products. We are cooperating with this inquiry. In 2017, we received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts requesting documents related to our copay coupon program and Medicaid price reporting methodology. We are cooperating with this inquiry. In 2017, we received a voluntary request for information from the U.S. Attorney’s Office for the Eastern District of Pennsylvania requesting information related to our reimbursement support offerings, clinical education programs and interactions with specialty pharmacies for Sovaldi and Harvoni. In 2018, we received another voluntary request for information related to our speaker programs and advisory boards for our HCV and hepatitis B virus (HBV) products. We are cooperating with these voluntary requests. In 2017, we received a subpoena from the California Department of Insurance and the Alameda County District Attorney’s Office requesting documents related to our marketing activities, reimbursement support offerings, clinical education programs and interactions with specialty pharmacies for Harvoni and Sovaldi. We are cooperating with this inquiry. In 2017, we received a subpoena from the U.S. Department of Health and Human Services requesting documents related to our Frontlines of Communities in the United States (FOCUS) program. We cooperated with the inquiry, and in February 2019, the government informed us that it declined to intervene in the False Claims Act qui tam lawsuit related to the inquiry. In March 2019, the relator filed a voluntary dismissal of the qui tam lawsuit without prejudice as to all claims. In 2017, we also received a subpoena from the U.S. Attorney’s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry. Product Liability We have been named as a defendant in one class action lawsuit filed in 2018 and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to suffer kidney and/or bone injuries. The lawsuits, all of which are pending in state or federal court in California, involve hundreds of plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages. Other Matters We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated business, financial position or results of operations. |
Stockholders' Equity
Stockholders' Equity | 3 Months Ended |
Mar. 31, 2019 | |
Equity [Abstract] | |
Stockholders' Equity | STOCKHOLDERS’ EQUITY Stock Repurchase Program In the first quarter of 2016, our Board of Directors authorized a $12.0 billion stock repurchase program ( 2016 Program ) under which repurchases may be made in the open market or in privately negotiated transactions. We started repurchases under the 2016 Program in April 2016. During the three months ended March 31, 2019 and 2018 , we repurchased and retired 12 million and 13 million shares of our common stock for $834 million and $1.0 billion , respectively, through open market transactions under the 2016 Program . As of March 31, 2019 , the remaining authorized repurchase amount under the 2016 Program was $4.3 billion . Accumulated Other Comprehensive Income (Loss) The following table summarizes the changes in AOCI by component, net of tax during the three months ended March 31, 2019 and 2018 (in millions): Foreign Currency Translation Unrealized Gains and Losses on Available-for-Sale Debt Securities Unrealized Gains and Losses on Cash Flow Hedges Total Balance at December 31, 2018 $ 47 $ (52 ) $ 85 $ 80 Net unrealized gain 21 30 28 79 Reclassifications to net income — — (29 ) (29 ) Net current period other comprehensive income (loss) 21 30 (1 ) 50 Balance at March 31, 2019 $ 68 $ (22 ) $ 84 $ 130 Foreign Currency Translation Unrealized Gains and Losses on Available-for-Sale Debt Securities Unrealized Gains and Losses on Cash Flow Hedges Total Balance at December 31, 2017 $ 85 $ 194 $ (114 ) $ 165 Reclassifications to retained earnings as a result of the adoption of new accounting standards — (293 ) — (293 ) Balance at January 1, 2018 85 (99 ) (114 ) (128 ) Net unrealized gain (loss) 7 (36 ) (61 ) (90 ) Reclassifications to net income — — 48 48 Net current period other comprehensive income (loss) 7 (36 ) (13 ) (42 ) Balance at March 31, 2018 $ 92 $ (135 ) $ (127 ) $ (170 ) The amounts reclassified to net income for gains and losses on cash flow hedges are recorded as part of Product sales on our Condensed Consolidated Statements of Income. See Note 5 . Derivative Financial Instruments for additional information. The amounts reclassified to net income for gains and losses on available-for-sale debt securities are recorded as part of Other income (expense), net on our Condensed Consolidated Statements of Income. The income tax impact allocated to each component of other comprehensive income was not material for any period presented. |
Net Income Per Share Attributab
Net Income Per Share Attributable to Gilead Common Stockholders | 3 Months Ended |
Mar. 31, 2019 | |
Earnings Per Share [Abstract] | |
Net Income Per Share Attributable to Gilead Common Stockholders | NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS Basic net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding during the period. Diluted net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents were determined under the treasury stock method. Potential shares of common stock excluded from the computation of diluted net income per share attributable to Gilead common stockholders because their effect would have been antidilutive were 16 million and 12 million shares for the three months ended March 31, 2019 and 2018 , respectively. The following table summarizes the calculation of basic and diluted net income per share attributable to Gilead common stockholders (in millions, except per share amounts): Three Months Ended March 31, 2019 2018 Net income attributable to Gilead $ 1,975 $ 1,538 Shares used in per share calculation - basic 1,276 1,307 Dilutive effect of stock options and equivalents 7 13 Shares used in per share calculation - diluted 1,283 1,320 Net income per share attributable to Gilead common stockholders - basic $ 1.55 $ 1.18 Net income per share attributable to Gilead common stockholders - diluted $ 1.54 $ 1.17 |
Segment Information
Segment Information | 3 Months Ended |
Mar. 31, 2019 | |
Segment Reporting [Abstract] | |
Segment Information | SEGMENT INFORMATION We have one operating segment, which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Therefore, our results of operations are reported on a consolidated basis consistent with internal management reporting reviewed by our chief operating decision maker, who is our chief executive officer. See Note 2 . Revenues for a summary of disaggregated revenues by product and geographic region. The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues): Three Months Ended March 31, 2019 2018 AmerisourceBergen Corp. 21 % 21 % Cardinal Health, Inc. 20 % 21 % McKesson Corp. 20 % 20 % |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2019 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | INCOME TAXES Our effective tax rate of 16.3% for the three months ended March 31, 2019 differed from the U.S. federal statutory rate of 21% primarily due to a $119 million tax benefit related to settlements with taxing authorities and earnings from non-U.S. subsidiaries that operate in jurisdictions with lower tax rates than the United States, partially offset by the tax on Global Intangible Low-Taxed Income, state taxes and our portion of the non-tax deductible branded prescription drug fee. Our effective tax rate of 24.3% for the three months ended March 31, 2018 differed from the U.S. federal statutory rate of 21% primarily due to a $49 million tax expense related to a settlement of a foreign tax examination, state taxes and our portion of the non-tax deductible branded prescription drug fee, partially offset by earnings from non-U.S. subsidiaries that operate in jurisdictions with lower tax rates than the United States. We file federal, state and foreign income tax returns in the United States and in many foreign jurisdictions. For federal and California income tax purposes, the statute of limitations is open for 2013 and 2010 onwards, respectively. Our income tax returns are subject to audit by federal, state and foreign tax authorities. We are currently under examination by the IRS for the tax years from 2013 to 2015 and by various state and foreign jurisdictions. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We regularly evaluate our exposures associated with our tax filing positions. We record liabilities related to uncertain tax positions in accordance with the income tax guidance which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period. Our unrecognized tax benefits decreased by $119 million during the three months ended March 31, 2019 due to settlements with taxing authorities. As of March 31, 2019 , we do not believe that it is reasonably possible that our unrecognized tax benefits will materially increase or decrease in the next 12 months. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The financial statements include all adjustments, consisting of normal recurring adjustments that the management of Gilead Sciences, Inc. (Gilead, we, our or us) believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period. The accompanying Condensed Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our Condensed Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. We assess whether we are the primary beneficiary of a variable interest entity (VIE) at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. As of March 31, 2019 , we did not have any material VIEs. The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December 31, 2018 , included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC). |
Significant Accounting Policies, Estimates and Judgments | Significant Accounting Policies, Estimates and Judgments The preparation of these Condensed Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Actual results may differ significantly from these estimates. |
Concentrations of Risk | Concentrations of Risk We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. We are also subject to credit risk from our accounts receivable related to our product sales. The majority of our trade accounts receivable arises from product sales in the United States and Europe. To date, we have not experienced significant losses with respect to the collection of our accounts receivable. We believe that our allowance for doubtful accounts was adequate as of March 31, 2019 . |
Recently Issued Accounting Standards | Recently Adopted Accounting Standards In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2016-02 “Leases” (ASU 2016-02) and subsequently issued supplemental adoption guidance and clarification (collectively, Topic 842). Topic 842 amends a number of aspects of lease accounting, including requiring lessees to recognize right-of-use assets and lease liabilities for operating leases with a lease term greater than one year. Topic 842 supersedes Topic 840 “Leases.” On January 1, 2019, we adopted Topic 842 using the modified retrospective approach. Results for reporting periods beginning after January 1, 2019 are presented under Topic 842, while prior period amounts are not adjusted and continue to be reported in accordance with our historical accounting under Topic 840. We elected the package of practical expedients permitted under the transition guidance within Topic 842, which allowed us to carry forward the historical lease classification, retain the initial direct costs for any leases that existed prior to the adoption of the standard and not reassess whether any contracts entered into prior to the adoption are leases. We also elected to account for lease and nonlease components in our lease agreements as a single lease component in determining lease assets and liabilities. In addition, we elected not to recognize the right-of-use assets and liabilities for leases with lease terms of one year or less. Upon adoption of Topic 842, we recorded $441 million of right-of-use assets within Other long-term assets and $ 490 million of operating lease liabilities, classified primarily within Other long-term obligations on our Condensed Consolidated Balance Sheet, as of January 1, 2019. The adoption did not have a material impact on our Condensed Consolidated Statements of Income or Condensed Consolidated Statements of Cash Flows. See Note 10 . Leases for additional information. Recently Issued Accounting Standards Not Yet Adopted In June 2016, the FASB issued Accounting Standards Update No. 2016-13 “Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments” (ASU 2016-13). ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within ASU 2019-04 “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments.” The guidance will become effective for us beginning in the first quarter of 2020 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted beginning in the first quarter of 2019. We are evaluating the impact of the adoption of these standards but we currently do not expect a material impact on our Condensed Consolidated Financial Statements. In November 2018, the FASB issued Accounting Standards Update No. 2018-18 “Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606” (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. This guidance will become effective for us beginning in the first quarter of 2020 and will be applied retrospectively to January 1, 2018 when we initially adopted Topic 606. Early adoption is permitted. We are evaluating the impact of the adoption of this standard but we currently do not expect a material impact on our |
Revenues Disaggregation of Reve
Revenues Disaggregation of Revenues (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Disaggregation of Revenue [Abstract] | |
Disaggregation of Revenues | The following table disaggregates our product sales by product and geographic region and disaggregates our royalty, contract and other revenues by geographic region (in millions): Three Months Ended March 31, 2019 Three Months Ended March 31, 2018 U.S. Europe Other International Total U.S. Europe Other International Total Product sales: Atripla $ 133 $ 16 $ 22 $ 171 $ 228 $ 51 $ 35 $ 314 Biktarvy 739 48 6 793 35 — — 35 Complera/Eviplera 44 62 9 115 67 109 14 190 Descovy 233 68 41 342 274 75 12 361 Genvoya 728 193 94 1,015 853 186 43 1,082 Odefsey 282 106 9 397 279 58 5 342 Stribild 67 18 11 96 133 29 12 174 Truvada 551 33 22 606 507 97 48 652 Other HIV (1) 11 1 5 17 9 1 3 13 Revenue share – Symtuza (2) 42 24 — 66 — 7 — 7 AmBisome 8 57 28 93 17 56 34 107 Ledipasvir/Sofosbuvir (3) 117 27 81 225 234 56 58 348 Letairis 197 — — 197 204 — — 204 Ranexa 155 — — 155 195 — — 195 Sofosbuvir/Velpatasvir (4) 230 154 107 491 269 198 69 536 Vemlidy 65 4 32 101 47 3 8 58 Viread 12 14 46 72 7 30 60 97 Vosevi 45 16 2 63 86 16 5 107 Yescarta 90 6 — 96 40 — — 40 Zydelig 11 15 1 27 14 18 1 33 Other (5) 36 20 6 62 29 15 62 106 Total product sales 3,796 882 522 5,200 3,527 1,005 469 5,001 Royalty, contract and other revenues 22 56 3 81 20 52 15 87 Total revenues $ 3,818 $ 938 $ 525 $ 5,281 $ 3,547 $ 1,057 $ 484 $ 5,088 ____________________ Notes: (1) Includes Emtriva and Tybost (2) Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland UC (Janssen) (3) Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC (4) Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC (5) Includes Cayston, Hepsera and Sovaldi |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Fair Value Disclosures [Abstract] | |
Summary of assets and liabilities measured at fair value | The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in millions): March 31, 2019 December 31, 2018 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Available-for-sale debt securities: U.S. treasury securities $ 4,782 $ — $ — $ 4,782 $ 3,969 $ — $ — $ 3,969 Certificates of deposit — 4,211 — 4,211 — 4,361 — 4,361 U.S. government agencies securities — 1,444 — 1,444 — 938 — 938 Municipal debt securities — 25 — 25 — — — — Non-U.S. government securities — 452 — 452 — 305 — 305 Corporate debt securities — 12,565 — 12,565 — 13,067 — 13,067 Residential mortgage and asset-backed securities — 1,036 — 1,036 — 1,524 — 1,524 Equity securities: Money market funds 3,778 — — 3,778 5,305 — — 5,305 Publicly traded equity securities 1,099 18 — 1,117 881 — — 881 Deferred compensation plan 150 — 150 124 — — 124 Foreign currency derivative contracts — 77 — 77 — 78 — 78 Total $ 9,809 $ 19,828 $ — $ 29,637 $ 10,279 $ 20,273 $ — $ 30,552 Liabilities: Deferred compensation plan $ 150 $ — $ — $ 150 $ 124 $ — $ — $ 124 Foreign currency derivative contracts — 2 — 2 — 1 — 1 Total $ 150 $ 2 $ — $ 152 $ 124 $ 1 $ — $ 125 |
Summary of Classification of Equity Securities | The following table summarizes the classification of our equity securities in our Condensed Consolidated Balance Sheets (in millions): March 31, 2019 December 31, 2018 Cash and cash equivalents $ 3,778 $ 5,305 Prepaid and other current assets 1,105 863 Other long-term assets 162 142 Total $ 5,045 $ 6,310 |
Available-for-Sale Debt Secur_2
Available-for-Sale Debt Securities (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Debt Securities, Available-for-sale [Abstract] | |
Reconciliation of Available-for-Sale Debt Securities from Cost Basis to Fair Value | The following table summarizes our available-for-sale debt securities (in millions): March 31, 2019 December 31, 2018 Amortized Gross Gross Estimated Amortized Gross Gross Estimated U.S. treasury securities $ 4,786 $ — $ (4 ) $ 4,782 $ 3,978 $ — $ (9 ) $ 3,969 Certificates of deposit 4,211 — — 4,211 4,361 — — 4,361 U.S. government agencies securities 1,446 — (2 ) 1,444 943 — (5 ) 938 Municipal debt securities 25 — — 25 — — — — Non-U.S. government securities 453 — (1 ) 452 307 — (2 ) 305 Corporate debt securities 12,576 1 (12 ) 12,565 13,095 1 (29 ) 13,067 Residential mortgage and asset-backed securities 1,040 — (4 ) 1,036 1,532 — (8 ) 1,524 Total $ 24,537 $ 1 $ (23 ) $ 24,515 $ 24,216 $ 1 $ (53 ) $ 24,164 |
Summary of Classification of Available-for-Sale Debt Securities | The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets (in millions): March 31, 2019 December 31, 2018 Cash and cash equivalents $ 11,317 $ 10,592 Short-term marketable securities 10,977 12,149 Long-term marketable securities 2,221 1,423 Total $ 24,515 $ 24,164 |
Summary of Available-for-Sale Debt Securities by Contractual Maturity | The following table summarizes our available-for-sale debt securities by contractual maturity (in millions): March 31, 2019 Amortized Cost Fair Value Within one year $ 22,313 $ 22,294 After one year through five years 2,175 2,172 After five years through ten years 31 31 After ten years 18 18 Total $ 24,537 $ 24,515 |
Summary of Available-for-Sale Debt Securities in a Continuous Loss Position Deemed not to be Other-than-Temporarily Impaired | The following table summarizes our available-for-sale debt securities that were in a continuous unrealized loss position, but were not deemed to be other-than-temporarily impaired (in millions): Less Than 12 Months 12 Months or Greater Total Gross Estimated Gross Estimated Gross Estimated March 31, 2019 U.S. treasury securities $ — $ 2,971 $ (4 ) $ 917 $ (4 ) $ 3,888 U.S. government agencies securities — 483 (2 ) 458 (2 ) 941 Non-U.S. government securities — 100 (1 ) 160 (1 ) 260 Corporate debt securities (1 ) 1,049 (11 ) 2,938 (12 ) 3,987 Residential mortgage and asset-backed securities — 85 (4 ) 817 (4 ) 902 Total $ (1 ) $ 4,688 $ (22 ) $ 5,290 $ (23 ) $ 9,978 December 31, 2018 U.S. treasury securities $ — $ 896 $ (9 ) $ 1,383 $ (9 ) $ 2,279 U.S. government agencies securities — 30 (5 ) 553 (5 ) 583 Non-U.S. government securities — 86 (2 ) 192 (2 ) 278 Corporate debt securities (1 ) 1,600 (28 ) 4,204 (29 ) 5,804 Residential mortgage and asset-backed securities — 192 (8 ) 1,186 (8 ) 1,378 Total $ (1 ) $ 2,804 $ (52 ) $ 7,518 $ (53 ) $ 10,322 |
Derivative Financial Instrume_2
Derivative Financial Instruments (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Summary of classification and fair value of derivative instruments | The following table summarizes the classification and fair values of derivative instruments in our Condensed Consolidated Balance Sheets (in millions): March 31, 2019 Asset Derivatives Liability Derivatives Classification Fair Value Classification Fair Value Derivatives designated as hedges: Foreign currency exchange contracts Other current assets $ 74 Other accrued liabilities $ (1 ) Foreign currency exchange contracts Other long-term assets 3 Other long-term obligations — Total derivatives designated as hedges 77 (1 ) Derivatives not designated as hedges: Foreign currency exchange contracts Other current assets — Other accrued liabilities (1 ) Total derivatives not designated as hedges — (1 ) Total derivatives $ 77 $ (2 ) December 31, 2018 Asset Derivatives Liability Derivatives Classification Fair Value Classification Fair Value Derivatives designated as hedges: Foreign currency exchange contracts Other current assets $ 73 Other accrued liabilities $ (1 ) Foreign currency exchange contracts Other long-term assets 5 Other long-term obligations — Total derivatives designated as hedges 78 (1 ) Derivatives not designated as hedges: Foreign currency exchange contracts Other current assets — Other accrued liabilities — Total derivatives not designated as hedges — — Total derivatives $ 78 $ (1 ) |
Summary of effect of foreign currency exchange contracts | The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements (in millions): Three Months Ended March 31, 2019 2018 Derivatives designated as hedges: Gains (losses) recognized in AOCI $ 28 $ (61 ) Gains (losses) reclassified from AOCI into product sales 29 (48 ) Derivatives not designated as hedges: Losses recognized in Other income (expense), net $ (6 ) $ (14 ) |
Summary of potential effect of offsetting derivatives | The following table summarizes the potential effect of offsetting derivatives by type of financial instrument on our Condensed Consolidated Balance Sheets (in millions): Gross Amounts Not Offset on our Condensed Consolidated Balance Sheets Description Gross Amounts of Recognized Assets/Liabilities Gross Amounts Offset on our Condensed Consolidated Balance Sheets Amounts of Assets/Liabilities Presented on our Condensed Consolidated Balance Sheets Derivative Financial Instruments Cash Collateral Received/ Pledged Net Amount (Legal Offset) As of March 31, 2019 Derivative assets $ 77 $ — $ 77 $ (2 ) $ — $ 75 Derivative liabilities (2 ) — (2 ) 2 — — As of December 31, 2018 Derivative assets $ 78 $ — $ 78 $ (1 ) $ — $ 77 Derivative liabilities (1 ) — (1 ) 1 — — |
Other Financial Information (Ta
Other Financial Information (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Other Financial Information [Abstract] | |
Schedule of Inventories | The following table summarizes our inventories (in millions): March 31, 2019 December 31, 2018 Raw materials $ 1,860 $ 1,888 Work in process 267 235 Finished goods 501 507 Total $ 2,628 $ 2,630 Reported as: Inventories $ 898 $ 814 Other long-term assets 1,730 1,816 Total $ 2,628 $ 2,630 |
Schedule of Other Accrued Liabilities | The following table summarizes the components of other accrued liabilities (in millions): March 31, 2019 December 31, 2018 Compensation and employee benefits $ 325 $ 555 Accrued payment for marketing-related rights acquired from Japan Tobacco Inc. 185 365 Other accrued expenses 1,838 2,219 Total $ 2,348 $ 3,139 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Intangible Assets, Net (Excluding Goodwill) [Abstract] | |
Schedule of Finite-Lived Intangible Assets | The following table summarizes our intangible assets, net (in millions): March 31, 2019 December 31, 2018 Gross Carrying Amount Accumulated Amortization Foreign Currency Translation Adjustment Net Carrying Amount Gross Carrying Amount Accumulated Amortization Foreign Currency Translation Adjustment Net Carrying Amount Finite-lived assets: Intangible asset - sofosbuvir $ 10,720 $ (3,729 ) $ — $ 6,991 $ 10,720 $ (3,554 ) $ — $ 7,166 Intangible asset - axicabtagene ciloleucel (DLBCL) 6,200 (502 ) — 5,698 6,200 (416 ) — 5,784 Intangible asset - Ranexa 688 (688 ) — — 688 (678 ) — 10 Other 1,098 (387 ) (4 ) 707 1,096 (359 ) (3 ) 734 Total finite-lived assets 18,706 (5,306 ) (4 ) 13,396 18,704 (5,007 ) (3 ) 13,694 Indefinite-lived assets - In Process Research & Development 2,047 — (5 ) 2,042 2,047 — (3 ) 2,044 Total intangible assets $ 20,753 $ (5,306 ) $ (9 ) $ 15,438 $ 20,751 $ (5,007 ) $ (6 ) $ 15,738 |
Schedule of Indefinite-Lived Intangible Assets | The following table summarizes our intangible assets, net (in millions): March 31, 2019 December 31, 2018 Gross Carrying Amount Accumulated Amortization Foreign Currency Translation Adjustment Net Carrying Amount Gross Carrying Amount Accumulated Amortization Foreign Currency Translation Adjustment Net Carrying Amount Finite-lived assets: Intangible asset - sofosbuvir $ 10,720 $ (3,729 ) $ — $ 6,991 $ 10,720 $ (3,554 ) $ — $ 7,166 Intangible asset - axicabtagene ciloleucel (DLBCL) 6,200 (502 ) — 5,698 6,200 (416 ) — 5,784 Intangible asset - Ranexa 688 (688 ) — — 688 (678 ) — 10 Other 1,098 (387 ) (4 ) 707 1,096 (359 ) (3 ) 734 Total finite-lived assets 18,706 (5,306 ) (4 ) 13,396 18,704 (5,007 ) (3 ) 13,694 Indefinite-lived assets - In Process Research & Development 2,047 — (5 ) 2,042 2,047 — (3 ) 2,044 Total intangible assets $ 20,753 $ (5,306 ) $ (9 ) $ 15,438 $ 20,751 $ (5,007 ) $ (6 ) $ 15,738 |
Schedule of Estimated Future Amortization Expense | The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March 31, 2019 (in millions): Fiscal Year Amount 2019 (remaining nine months) $ 851 2020 1,125 2021 1,125 2022 1,125 2023 1,125 Thereafter 8,045 Total $ 13,396 |
Debt and Credit Facilities (Tab
Debt and Credit Facilities (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Debt Disclosure [Abstract] | |
Summary of Debt Carrying Amount | The following table summarizes our borrowings under various financing arrangements (in millions): Carrying Amount Type of Borrowing Issue Date Due Date Interest Rate March 31, 2019 December 31, 2018 Senior Unsecured September 2017 March 2019 3-month LIBOR + 0.22% $ — $ 750 Senior Unsecured March 2014 April 2019 2.05% 500 500 Senior Unsecured September 2017 September 2019 1.85% 999 999 Senior Unsecured September 2017 September 2019 3-month LIBOR + 0.25% 500 499 Senior Unsecured November 2014 February 2020 2.35% 499 499 Senior Unsecured September 2015 September 2020 2.55% 1,997 1,996 Senior Unsecured March 2011 April 2021 4.50% 997 997 Senior Unsecured December 2011 December 2021 4.40% 1,247 1,247 Senior Unsecured September 2016 March 2022 1.95% 498 498 Senior Unsecured September 2015 September 2022 3.25% 997 997 Senior Unsecured September 2016 September 2023 2.50% 746 746 Senior Unsecured March 2014 April 2024 3.70% 1,744 1,744 Senior Unsecured November 2014 February 2025 3.50% 1,745 1,745 Senior Unsecured September 2015 March 2026 3.65% 2,732 2,731 Senior Unsecured September 2016 March 2027 2.95% 1,245 1,245 Senior Unsecured September 2015 September 2035 4.60% 990 990 Senior Unsecured September 2016 September 2036 4.00% 740 740 Senior Unsecured December 2011 December 2041 5.65% 995 995 Senior Unsecured March 2014 April 2044 4.80% 1,734 1,734 Senior Unsecured November 2014 February 2045 4.50% 1,731 1,730 Senior Unsecured September 2015 March 2046 4.75% 2,217 2,216 Senior Unsecured September 2016 March 2047 4.15% 1,725 1,724 Total debt, net 26,578 27,322 Less current portion 2,498 2,748 Total long-term debt, net $ 24,080 $ 24,574 |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Leases [Abstract] | |
Balance Sheet and Other Information Related to Operating Leases | The following table summarizes balance sheet and other information related to our operating leases as of March 31, 2019 (in millions, except weighted average data): Classification Amount Right-of-use assets, net Other long-term assets $ 455 Lease liabilities - current Other accrued liabilities $ 75 Lease liabilities - noncurrent Other long-term obligations $ 429 Weighted average remaining lease term 9.5 years Weighted average discount rate 3.61 % |
Supplemental Information Related to Operating Leases | The following table summarizes other supplemental information related to our operating leases (in millions): Three Months Ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities $ 18 Right-of-use assets obtained in exchange for lease liabilities $ 30 |
Operating Lease Aggregate Future Lease Payments | The following table summarizes a maturity analysis of our operating lease liabilities showing the aggregate lease payments as of March 31, 2019 (in millions): Fiscal Year Amount 2019 (remaining nine months) $ 69 2020 84 2021 72 2022 65 2023 57 Thereafter 257 Total undiscounted lease payments 604 Less: imputed interest (100 ) Total discounted lease payments $ 504 The following table summarizes the aggregate undiscounted non-cancelable future minimum lease payments for operating leases under the prior leases standard as of December 31, 2018 (in millions): Fiscal Year Amount 2019 $ 89 2020 78 2021 66 2022 60 2023 52 Thereafter 229 Total minimum lease payments $ 574 |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Equity [Abstract] | |
Summary of Changes in Accumulated Other Comprehensive Income (Loss) | Accumulated Other Comprehensive Income (Loss) The following table summarizes the changes in AOCI by component, net of tax during the three months ended March 31, 2019 and 2018 (in millions): Foreign Currency Translation Unrealized Gains and Losses on Available-for-Sale Debt Securities Unrealized Gains and Losses on Cash Flow Hedges Total Balance at December 31, 2018 $ 47 $ (52 ) $ 85 $ 80 Net unrealized gain 21 30 28 79 Reclassifications to net income — — (29 ) (29 ) Net current period other comprehensive income (loss) 21 30 (1 ) 50 Balance at March 31, 2019 $ 68 $ (22 ) $ 84 $ 130 Foreign Currency Translation Unrealized Gains and Losses on Available-for-Sale Debt Securities Unrealized Gains and Losses on Cash Flow Hedges Total Balance at December 31, 2017 $ 85 $ 194 $ (114 ) $ 165 Reclassifications to retained earnings as a result of the adoption of new accounting standards — (293 ) — (293 ) Balance at January 1, 2018 85 (99 ) (114 ) (128 ) Net unrealized gain (loss) 7 (36 ) (61 ) (90 ) Reclassifications to net income — — 48 48 Net current period other comprehensive income (loss) 7 (36 ) (13 ) (42 ) Balance at March 31, 2018 $ 92 $ (135 ) $ (127 ) $ (170 ) |
Net Income Per Share Attribut_2
Net Income Per Share Attributable to Gilead Common Stockholders (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Earnings Per Share [Abstract] | |
Schedule of the Calculation of Basic and Diluted Earnings Per Share | The following table summarizes the calculation of basic and diluted net income per share attributable to Gilead common stockholders (in millions, except per share amounts): Three Months Ended March 31, 2019 2018 Net income attributable to Gilead $ 1,975 $ 1,538 Shares used in per share calculation - basic 1,276 1,307 Dilutive effect of stock options and equivalents 7 13 Shares used in per share calculation - diluted 1,283 1,320 Net income per share attributable to Gilead common stockholders - basic $ 1.55 $ 1.18 Net income per share attributable to Gilead common stockholders - diluted $ 1.54 $ 1.17 |
Segment Information (Tables)
Segment Information (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Segment Reporting [Abstract] | |
Summary of Revenue by Major Customers | The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues): Three Months Ended March 31, 2019 2018 AmerisourceBergen Corp. 21 % 21 % Cardinal Health, Inc. 20 % 21 % McKesson Corp. 20 % 20 % |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies Accounting Standards Adoption 2016-02 (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Jan. 01, 2019 |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Right-of-use assets, net | $ 455 | |
Operating Lease, Liability | $ 504 | |
Accounting Standards Update 2016-02 [Member] | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Right-of-use assets, net | $ 441 | |
Operating Lease, Liability | $ 490 |
Revenues (Details)
Revenues (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Disaggregation of Revenue [Line Items] | ||
Revenues | $ 5,281 | $ 5,088 |
Revenues | 5,281 | 5,088 |
U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 3,818 | 3,547 |
Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 938 | 1,057 |
Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 525 | 484 |
Atripla | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 171 | 314 |
Atripla | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 133 | 228 |
Atripla | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 16 | 51 |
Atripla | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 22 | 35 |
Biktarvy | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 793 | 35 |
Biktarvy | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 739 | 35 |
Biktarvy | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 48 | 0 |
Biktarvy | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 6 | 0 |
Complera/Eviplera | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 115 | 190 |
Complera/Eviplera | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 44 | 67 |
Complera/Eviplera | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 62 | 109 |
Complera/Eviplera | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 9 | 14 |
Descovy | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 342 | 361 |
Descovy | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 233 | 274 |
Descovy | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 68 | 75 |
Descovy | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 41 | 12 |
Genvoya | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 1,015 | 1,082 |
Genvoya | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 728 | 853 |
Genvoya | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 193 | 186 |
Genvoya | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 94 | 43 |
Odefsey | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 397 | 342 |
Odefsey | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 282 | 279 |
Odefsey | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 106 | 58 |
Odefsey | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 9 | 5 |
Stribild | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 96 | 174 |
Stribild | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 67 | 133 |
Stribild | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 18 | 29 |
Stribild | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 11 | 12 |
Truvada | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 606 | 652 |
Truvada | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 551 | 507 |
Truvada | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 33 | 97 |
Truvada | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 22 | 48 |
Other HIV | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 17 | 13 |
Other HIV | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 11 | 9 |
Other HIV | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 1 | 1 |
Other HIV | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 5 | 3 |
Revenue share - Symtuza | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 66 | 7 |
Revenue share - Symtuza | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 42 | 0 |
Revenue share - Symtuza | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 24 | 7 |
Revenue share - Symtuza | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 0 | 0 |
AmBisome | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 93 | 107 |
AmBisome | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 8 | 17 |
AmBisome | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 57 | 56 |
AmBisome | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 28 | 34 |
Ledipasvir/Sofosbuvir | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 225 | 348 |
Ledipasvir/Sofosbuvir | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 117 | 234 |
Ledipasvir/Sofosbuvir | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 27 | 56 |
Ledipasvir/Sofosbuvir | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 81 | 58 |
Letairis | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 197 | 204 |
Letairis | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 197 | 204 |
Letairis | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 0 | 0 |
Letairis | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 0 | 0 |
Ranexa | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 155 | 195 |
Ranexa | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 155 | 195 |
Ranexa | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 0 | 0 |
Ranexa | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 0 | 0 |
Sofosbuvir/Velpatasvir | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 491 | 536 |
Sofosbuvir/Velpatasvir | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 230 | 269 |
Sofosbuvir/Velpatasvir | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 154 | 198 |
Sofosbuvir/Velpatasvir | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 107 | 69 |
Vemlidy | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 101 | 58 |
Vemlidy | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 65 | 47 |
Vemlidy | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 4 | 3 |
Vemlidy | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 32 | 8 |
Viread | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 72 | 97 |
Viread | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 12 | 7 |
Viread | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 14 | 30 |
Viread | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 46 | 60 |
Vosevi | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 63 | 107 |
Vosevi | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 45 | 86 |
Vosevi | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 16 | 16 |
Vosevi | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 2 | 5 |
Yescarta | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 96 | 40 |
Yescarta | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 90 | 40 |
Yescarta | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 6 | 0 |
Yescarta | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 0 | 0 |
Zydelig | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 27 | 33 |
Zydelig | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 11 | 14 |
Zydelig | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 15 | 18 |
Zydelig | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 1 | 1 |
Other(3) | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 62 | 106 |
Other(3) | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 36 | 29 |
Other(3) | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 20 | 15 |
Other(3) | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 6 | 62 |
Product sales | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 5,200 | 5,001 |
Product sales | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 3,796 | 3,527 |
Product sales | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 882 | 1,005 |
Product sales | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 522 | 469 |
Royalty, contract and other revenues | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 81 | 87 |
Revenues | 81 | 87 |
Royalty, contract and other revenues | U.S. | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 22 | 20 |
Royalty, contract and other revenues | Europe | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | 56 | 52 |
Royalty, contract and other revenues | Other International | ||
Disaggregation of Revenue [Line Items] | ||
Revenues | $ 3 | $ 15 |
Revenues Revenues Recognized fr
Revenues Revenues Recognized from Performance Obligations Satisfied in Prior Periods (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Contract with Customer, Performance Obligation Satisfied in Previous Period [Line Items] | ||
Contract with Customer, Performance Obligation Satisfied in Previous Period | $ 155 | $ 97 |
Change in estimate variable consideration [Member] | ||
Contract with Customer, Performance Obligation Satisfied in Previous Period [Line Items] | ||
Contract with Customer, Performance Obligation Satisfied in Previous Period | $ 107 | $ 87 |
Revenues Contract Assets (Detai
Revenues Contract Assets (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Contract Assets [Abstract] | ||
Contract assets | $ 140 | $ 125 |
Fair Value Measurements Summary
Fair Value Measurements Summary of assets and liabilities measured at fair value (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Assets: | ||
Available-for-sale debt securities | $ 24,515 | $ 24,164 |
Total | 5,045 | 6,310 |
Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | ||
Assets: | ||
Total | 29,637 | 30,552 |
Liabilities: | ||
Total | 152 | 125 |
Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | U.S. treasury securities | ||
Assets: | ||
Available-for-sale debt securities | 4,782 | 3,969 |
Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Certificates of deposit | ||
Assets: | ||
Available-for-sale debt securities | 4,211 | 4,361 |
Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | U.S. government agencies securities | ||
Assets: | ||
Available-for-sale debt securities | 1,444 | 938 |
Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Municipal debt securities | ||
Assets: | ||
Available-for-sale debt securities | 25 | 0 |
Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Non-U.S. government securities | ||
Assets: | ||
Available-for-sale debt securities | 452 | 305 |
Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Corporate debt securities | ||
Assets: | ||
Available-for-sale debt securities | 12,565 | 13,067 |
Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Residential mortgage and asset-backed securities | ||
Assets: | ||
Available-for-sale debt securities | 1,036 | 1,524 |
Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Money market funds | ||
Assets: | ||
Marketable equity securities | 3,778 | 5,305 |
Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Publicly traded equity securities | ||
Assets: | ||
Marketable equity securities | 1,117 | 881 |
Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Deferred compensation plan | ||
Assets: | ||
Marketable equity securities | 150 | 124 |
Liabilities: | ||
Deferred compensation plan | 150 | 124 |
Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Foreign currency derivative contracts | ||
Assets: | ||
Foreign currency derivative contracts | 77 | 78 |
Liabilities: | ||
Foreign currency derivative contracts | 2 | 1 |
Fair Value, Measurements, Recurring | Level 1 | ||
Assets: | ||
Total | 9,809 | 10,279 |
Liabilities: | ||
Total | 150 | 124 |
Fair Value, Measurements, Recurring | Level 1 | U.S. treasury securities | ||
Assets: | ||
Available-for-sale debt securities | 4,782 | 3,969 |
Fair Value, Measurements, Recurring | Level 1 | Certificates of deposit | ||
Assets: | ||
Available-for-sale debt securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 1 | U.S. government agencies securities | ||
Assets: | ||
Available-for-sale debt securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 1 | Municipal debt securities | ||
Assets: | ||
Available-for-sale debt securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 1 | Non-U.S. government securities | ||
Assets: | ||
Available-for-sale debt securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 1 | Corporate debt securities | ||
Assets: | ||
Available-for-sale debt securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 1 | Residential mortgage and asset-backed securities | ||
Assets: | ||
Available-for-sale debt securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 1 | Money market funds | ||
Assets: | ||
Marketable equity securities | 3,778 | 5,305 |
Fair Value, Measurements, Recurring | Level 1 | Publicly traded equity securities | ||
Assets: | ||
Marketable equity securities | 1,099 | 881 |
Fair Value, Measurements, Recurring | Level 1 | Deferred compensation plan | ||
Assets: | ||
Marketable equity securities | 150 | 124 |
Liabilities: | ||
Deferred compensation plan | 150 | 124 |
Fair Value, Measurements, Recurring | Level 1 | Foreign currency derivative contracts | ||
Assets: | ||
Foreign currency derivative contracts | 0 | 0 |
Liabilities: | ||
Foreign currency derivative contracts | 0 | 0 |
Fair Value, Measurements, Recurring | Level 2 | ||
Assets: | ||
Total | 19,828 | 20,273 |
Liabilities: | ||
Total | 2 | 1 |
Fair Value, Measurements, Recurring | Level 2 | U.S. treasury securities | ||
Assets: | ||
Available-for-sale debt securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 2 | Certificates of deposit | ||
Assets: | ||
Available-for-sale debt securities | 4,211 | 4,361 |
Fair Value, Measurements, Recurring | Level 2 | U.S. government agencies securities | ||
Assets: | ||
Available-for-sale debt securities | 1,444 | 938 |
Fair Value, Measurements, Recurring | Level 2 | Municipal debt securities | ||
Assets: | ||
Available-for-sale debt securities | 25 | 0 |
Fair Value, Measurements, Recurring | Level 2 | Non-U.S. government securities | ||
Assets: | ||
Available-for-sale debt securities | 452 | 305 |
Fair Value, Measurements, Recurring | Level 2 | Corporate debt securities | ||
Assets: | ||
Available-for-sale debt securities | 12,565 | 13,067 |
Fair Value, Measurements, Recurring | Level 2 | Residential mortgage and asset-backed securities | ||
Assets: | ||
Available-for-sale debt securities | 1,036 | 1,524 |
Fair Value, Measurements, Recurring | Level 2 | Money market funds | ||
Assets: | ||
Marketable equity securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 2 | Publicly traded equity securities | ||
Assets: | ||
Marketable equity securities | 18 | 0 |
Fair Value, Measurements, Recurring | Level 2 | Deferred compensation plan | ||
Assets: | ||
Marketable equity securities | 0 | |
Liabilities: | ||
Deferred compensation plan | 0 | 0 |
Fair Value, Measurements, Recurring | Level 2 | Foreign currency derivative contracts | ||
Assets: | ||
Foreign currency derivative contracts | 77 | 78 |
Liabilities: | ||
Foreign currency derivative contracts | 2 | 1 |
Fair Value, Measurements, Recurring | Level 3 | ||
Assets: | ||
Total | 0 | 0 |
Liabilities: | ||
Total | 0 | 0 |
Fair Value, Measurements, Recurring | Level 3 | U.S. treasury securities | ||
Assets: | ||
Available-for-sale debt securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 3 | Certificates of deposit | ||
Assets: | ||
Available-for-sale debt securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 3 | U.S. government agencies securities | ||
Assets: | ||
Available-for-sale debt securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 3 | Municipal debt securities | ||
Assets: | ||
Available-for-sale debt securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 3 | Non-U.S. government securities | ||
Assets: | ||
Available-for-sale debt securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 3 | Corporate debt securities | ||
Assets: | ||
Available-for-sale debt securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 3 | Residential mortgage and asset-backed securities | ||
Assets: | ||
Available-for-sale debt securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 3 | Money market funds | ||
Assets: | ||
Marketable equity securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 3 | Publicly traded equity securities | ||
Assets: | ||
Marketable equity securities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 3 | Deferred compensation plan | ||
Assets: | ||
Marketable equity securities | 0 | 0 |
Liabilities: | ||
Deferred compensation plan | 0 | 0 |
Fair Value, Measurements, Recurring | Level 3 | Foreign currency derivative contracts | ||
Assets: | ||
Foreign currency derivative contracts | 0 | 0 |
Liabilities: | ||
Foreign currency derivative contracts | $ 0 | $ 0 |
Fair Value Measurements Summa_2
Fair Value Measurements Summary of Classification on Balance Sheet (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Total | $ 5,045 | $ 6,310 |
Cash and cash equivalents | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable equity securities | 3,778 | 5,305 |
Prepaid and other current assets | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable equity securities | 1,105 | 863 |
Other long-term assets | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Marketable equity securities | $ 162 | $ 142 |
Fair Value Measurements Additio
Fair Value Measurements Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Unrealized gain on investment of equity securities | $ 197 | $ 45 | |
Short-term and long-term debt | 26,578 | $ 27,322 | |
Market value | Level 2 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Short-term and long-term debt | 27,300 | $ 27,100 | |
Carrying value | Level 2 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Short-term and long-term debt | $ 26,600 |
Available-for-Sale Debt Secur_3
Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Available-for-Sale Debt Securities | ||
Amortized Cost | $ 24,537 | $ 24,216 |
Gross Unrealized Gains | 1 | 1 |
Gross Unrealized Losses | (23) | (53) |
Available-for-sale debt securities | 24,515 | 24,164 |
U.S. treasury securities | ||
Available-for-Sale Debt Securities | ||
Amortized Cost | 4,786 | 3,978 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | (4) | (9) |
Available-for-sale debt securities | 4,782 | 3,969 |
Certificates of deposit | ||
Available-for-Sale Debt Securities | ||
Amortized Cost | 4,211 | 4,361 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Available-for-sale debt securities | 4,211 | 4,361 |
U.S. government agencies securities | ||
Available-for-Sale Debt Securities | ||
Amortized Cost | 1,446 | 943 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | (2) | (5) |
Available-for-sale debt securities | 1,444 | 938 |
Municipal debt securities | ||
Available-for-Sale Debt Securities | ||
Amortized Cost | 25 | 0 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Available-for-sale debt securities | 25 | 0 |
Non-U.S. government securities | ||
Available-for-Sale Debt Securities | ||
Amortized Cost | 453 | 307 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | (1) | (2) |
Available-for-sale debt securities | 452 | 305 |
Corporate debt securities | ||
Available-for-Sale Debt Securities | ||
Amortized Cost | 12,576 | 13,095 |
Gross Unrealized Gains | 1 | 1 |
Gross Unrealized Losses | (12) | (29) |
Available-for-sale debt securities | 12,565 | 13,067 |
Residential mortgage and asset-backed securities | ||
Available-for-Sale Debt Securities | ||
Amortized Cost | 1,040 | 1,532 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | (4) | (8) |
Available-for-sale debt securities | $ 1,036 | $ 1,524 |
Available-for-Sale Debt Secur_4
Available-for-Sale Debt Securities - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Available-for-Sale Debt Securities | ||
Available-for-sale debt securities | $ 24,515 | $ 24,164 |
Cash and cash equivalents | ||
Available-for-Sale Debt Securities | ||
Available-for-sale debt securities | 11,317 | 10,592 |
Short-term marketable securities | ||
Available-for-Sale Debt Securities | ||
Available-for-sale debt securities | 10,977 | 12,149 |
Long-term marketable securities | ||
Available-for-Sale Debt Securities | ||
Available-for-sale debt securities | $ 2,221 | $ 1,423 |
Available-for-Sale Debt Secur_5
Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Amortized Cost | ||
Within one year | $ 22,313 | |
After one year through five years | 2,175 | |
After five years through ten years | 31 | |
After ten years | 18 | |
Amortized Cost | 24,537 | $ 24,216 |
Fair Value | ||
Within one year | 22,294 | |
After one year through five years | 2,172 | |
After five years through ten years | 31 | |
After ten years | 18 | |
Available-for-sale debt securities | $ 24,515 | $ 24,164 |
Available-for-Sale Debt Secur_6
Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities in a Continuous Unrealized Loss Position Deemed not to be Other-than-Temporarily Impaired (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Available-for-Sale Debt Securities | ||
Less than 12 Months, Unrealized Losses | $ (1) | $ (1) |
Less than 12 Months, Fair Value | 4,688 | 2,804 |
12 Months or Greater, Unrealized Losses | (22) | (52) |
12 Months or Greater, Fair Value | 5,290 | 7,518 |
Gross Unrealized Losses | (23) | (53) |
Total Estimated Fair Value | 9,978 | 10,322 |
U.S. treasury securities | ||
Available-for-Sale Debt Securities | ||
Less than 12 Months, Unrealized Losses | 0 | 0 |
Less than 12 Months, Fair Value | 2,971 | 896 |
12 Months or Greater, Unrealized Losses | (4) | (9) |
12 Months or Greater, Fair Value | 917 | 1,383 |
Gross Unrealized Losses | (4) | (9) |
Total Estimated Fair Value | 3,888 | 2,279 |
U.S. government agencies securities | ||
Available-for-Sale Debt Securities | ||
Less than 12 Months, Unrealized Losses | 0 | 0 |
Less than 12 Months, Fair Value | 483 | 30 |
12 Months or Greater, Unrealized Losses | (2) | (5) |
12 Months or Greater, Fair Value | 458 | 553 |
Gross Unrealized Losses | (2) | (5) |
Total Estimated Fair Value | 941 | 583 |
Non-U.S. government securities | ||
Available-for-Sale Debt Securities | ||
Less than 12 Months, Unrealized Losses | 0 | 0 |
Less than 12 Months, Fair Value | 100 | 86 |
12 Months or Greater, Unrealized Losses | (1) | (2) |
12 Months or Greater, Fair Value | 160 | 192 |
Gross Unrealized Losses | (1) | (2) |
Total Estimated Fair Value | 260 | 278 |
Corporate debt securities | ||
Available-for-Sale Debt Securities | ||
Less than 12 Months, Unrealized Losses | (1) | (1) |
Less than 12 Months, Fair Value | 1,049 | 1,600 |
12 Months or Greater, Unrealized Losses | (11) | (28) |
12 Months or Greater, Fair Value | 2,938 | 4,204 |
Gross Unrealized Losses | (12) | (29) |
Total Estimated Fair Value | 3,987 | 5,804 |
Residential mortgage and asset-backed securities | ||
Available-for-Sale Debt Securities | ||
Less than 12 Months, Unrealized Losses | 0 | 0 |
Less than 12 Months, Fair Value | 85 | 192 |
12 Months or Greater, Unrealized Losses | (4) | (8) |
12 Months or Greater, Fair Value | 817 | 1,186 |
Gross Unrealized Losses | (4) | (8) |
Total Estimated Fair Value | $ 902 | $ 1,378 |
Available-for-Sale Debt Secur_7
Available-for-Sale Debt Securities - Additional Information (Details) $ in Millions | 3 Months Ended | 12 Months Ended |
Mar. 31, 2019USD ($)position | Dec. 31, 2018USD ($)position | |
Debt Securities, Available-for-sale [Abstract] | ||
Securities in unrealized loss positions, number of positions (securities) | position | 915 | 1,348 |
Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale | $ | $ 0 | $ 0 |
Derivative Financial Instrume_3
Derivative Financial Instruments - Summary of Classification and Fair Value of Derivative Instruments (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Derivatives, Fair Value [Line Items] | ||
Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement | $ 77 | $ 78 |
Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement | 2 | 1 |
Designated as Hedging Instrument | ||
Derivatives, Fair Value [Line Items] | ||
Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement | 77 | 78 |
Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement | 1 | 1 |
Designated as Hedging Instrument | Other current assets | ||
Derivatives, Fair Value [Line Items] | ||
Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement | 74 | 73 |
Designated as Hedging Instrument | Other accrued liabilities | ||
Derivatives, Fair Value [Line Items] | ||
Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement | 1 | 1 |
Designated as Hedging Instrument | Other long-term assets | ||
Derivatives, Fair Value [Line Items] | ||
Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement | 3 | 5 |
Designated as Hedging Instrument | Other long-term obligations | ||
Derivatives, Fair Value [Line Items] | ||
Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement | 0 | 0 |
Not Designated as Hedging Instrument | ||
Derivatives, Fair Value [Line Items] | ||
Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement | 0 | 0 |
Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement | 1 | 0 |
Not Designated as Hedging Instrument | Other current assets | ||
Derivatives, Fair Value [Line Items] | ||
Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement | 0 | 0 |
Not Designated as Hedging Instrument | Other accrued liabilities | ||
Derivatives, Fair Value [Line Items] | ||
Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement | $ 1 | $ 0 |
Derivative Financial Instrume_4
Derivative Financial Instruments - Summary of Effect of Foreign Currency Exchange Contracts (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ||
Gains (losses) recognized in AOCI | $ 28 | $ (61) |
Gains (losses) reclassified from AOCI into product sales | 29 | (48) |
Gains (losses) recognized in Other income (expense), net | $ (6) | $ (14) |
Derivative Financial Instrume_5
Derivative Financial Instruments - Summary of Potential Effect of Offsetting Derivatives (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Derivative Asset [Abstract] | ||
Gross Amounts of Recognized Assets/Liabilities | $ 77 | $ 78 |
Gross Amounts Offset on our Condensed Consolidated Balance Sheets | 0 | 0 |
Amounts of Assets/Liabilities Presented on our Condensed Consolidated Balance Sheets | 77 | 78 |
Derivative Financial Instruments | (2) | (1) |
Cash Collateral Received/ Pledged | 0 | 0 |
Net Amount (Legal Offset) | 75 | 77 |
Derivative Liability [Abstract] | ||
Gross Amounts of Recognized Assets/Liabilities | (2) | (1) |
Gross Amounts Offset on our Condensed Consolidated Balance Sheets | 0 | 0 |
Amounts of Assets/Liabilities Presented on our Condensed Consolidated Balance Sheets | (2) | (1) |
Derivative Financial Instruments | 2 | 1 |
Cash Collateral Received/ Pledged | 0 | 0 |
Net Amount (Legal Offset) | $ 0 | $ 0 |
Derivative Financial Instrume_6
Derivative Financial Instruments - Additional Information (Details) - USD ($) $ in Billions | 3 Months Ended | |
Mar. 31, 2019 | Dec. 31, 2018 | |
Derivative [Line Items] | ||
Notional amounts on foreign currency exchange contracts | $ 2.5 | $ 2.2 |
Maximum | ||
Derivative [Line Items] | ||
Maturity on derivative instruments | 18 months | |
Estimate of time to transfer | 12 months |
Collaborative Arrangements - Co
Collaborative Arrangements - Collaborative Arrangements Narrative (Details) $ in Millions | 3 Months Ended |
Mar. 31, 2019USD ($) | |
Collaborative Arrangements [Abstract] | |
Collaboration Agreement, Initial Consideration Transferred | $ 165 |
Other Research and Development Expense | $ 126 |
Other Financial Information Inv
Other Financial Information Inventories (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Other Financial Information [Abstract] | ||
Raw materials | $ 1,860 | $ 1,888 |
Work in process | 267 | 235 |
Finished goods | 501 | 507 |
Total | 2,628 | 2,630 |
Inventories | 898 | 814 |
Other long-term assets | 1,730 | 1,816 |
Total | $ 2,628 | $ 2,630 |
Other Financial Information Oth
Other Financial Information Other Accrued Liabilities (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Other Financial Information [Abstract] | ||
Compensation and employee benefits | $ 325 | $ 555 |
Accrued Liabilities and Other Liabilities | 185 | 365 |
Other accrued expenses | 1,838 | 2,219 |
Total | $ 2,348 | $ 3,139 |
Intangible Assets - Summary of
Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended |
Mar. 31, 2019 | Dec. 31, 2018 | |
Intangible Assets, Net (Excluding Goodwill) [Abstract] | ||
Gross Carrying Amount | $ 20,753 | $ 20,751 |
Foreign Currency Translation Adjustment | (9) | (6) |
Intangible assets, net | 15,438 | 15,738 |
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 18,706 | 18,704 |
Accumulated Amortization | 5,306 | 5,007 |
Foreign Currency Translation Adjustment | (4) | (3) |
Net Carrying Amount | 13,396 | 13,694 |
Indefinite-lived assets - In Process Research & Development | ||
Indefinite-lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 2,047 | 2,047 |
Net Carrying Amount | 2,042 | 2,044 |
In Process Research and Development [Member] | ||
Indefinite-lived Intangible Assets [Line Items] | ||
Indefinite-lived Intangible Assets, Foreign Currency Translation Gain (Loss) | (5) | (3) |
Intangible asset - sofosbuvir | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 10,720 | 10,720 |
Accumulated Amortization | 3,729 | 3,554 |
Foreign Currency Translation Adjustment | 0 | 0 |
Net Carrying Amount | 6,991 | 7,166 |
Intangible asset - axicabtagene ciloleucel (DLBCL) | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 6,200 | 6,200 |
Accumulated Amortization | 502 | 416 |
Foreign Currency Translation Adjustment | 0 | 0 |
Net Carrying Amount | 5,698 | 5,784 |
Intangible asset - Ranexa | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 688 | 688 |
Accumulated Amortization | 688 | 678 |
Foreign Currency Translation Adjustment | 0 | 0 |
Net Carrying Amount | 0 | 10 |
Other | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 1,098 | 1,096 |
Accumulated Amortization | 387 | 359 |
Foreign Currency Translation Adjustment | (4) | (3) |
Net Carrying Amount | $ 707 | $ 734 |
Intangible Assets - Schedule of
Intangible Assets - Schedule of Estimated Future Amortization Expense (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Intangible Assets, Net (Excluding Goodwill) [Abstract] | ||
2019 (remaining nine months) | $ 851 | |
2020 | 1,125 | |
2021 | 1,125 | |
2022 | 1,125 | |
2023 | 1,125 | |
Thereafter | 8,045 | |
Total | $ 13,396 | $ 13,694 |
Intangible Assets - Additional
Intangible Assets - Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Intangible Assets, Net (Excluding Goodwill) [Abstract] | ||
Amortization of Intangible Assets | $ 299 | $ 301 |
Debt and Credit Facilities Summ
Debt and Credit Facilities Summary of Debt Carrying Amount (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Dec. 31, 2018 | |
Debt Instrument [Line Items] | ||
Short-term and long-term debt | $ 26,578 | $ 27,322 |
Long-term Debt, Current Maturities | 2,498 | 2,748 |
Total long-term debt, net | 24,080 | 24,574 |
Unsecured Debt | 2017 Senior Unsecured Notes Due in March 2019 | ||
Debt Instrument [Line Items] | ||
Long-term debt | $ 0 | 750 |
Unsecured Debt | Senior Unsecured Notes Due in April 2019 | ||
Debt Instrument [Line Items] | ||
Interest Rate | 2.05% | |
Long-term debt | $ 500 | 500 |
Unsecured Debt | 2017 Senior Unsecured Notes Due in September 2019 with Fixed Rate | ||
Debt Instrument [Line Items] | ||
Interest Rate | 1.85% | |
Long-term debt | $ 999 | 999 |
Unsecured Debt | 2017 Senior Unsecured Notes Due in September 2019 with Floating Rate | ||
Debt Instrument [Line Items] | ||
Long-term debt | $ 500 | 499 |
Unsecured Debt | Senior Unsecured Notes Due In February 2020 | ||
Debt Instrument [Line Items] | ||
Interest Rate | 2.35% | |
Long-term debt | $ 499 | 499 |
Unsecured Debt | Senior Unsecured Notes Due in September 2020 | ||
Debt Instrument [Line Items] | ||
Interest Rate | 2.55% | |
Long-term debt | $ 1,997 | 1,996 |
Unsecured Debt | Senior Unsecured Notes Due in April 2021 | ||
Debt Instrument [Line Items] | ||
Interest Rate | 4.50% | |
Long-term debt | $ 997 | 997 |
Unsecured Debt | Senior Unsecured Notes Due In December 2021 | ||
Debt Instrument [Line Items] | ||
Interest Rate | 4.40% | |
Long-term debt | $ 1,247 | 1,247 |
Unsecured Debt | Senior Unsecured Notes Due in March 2022 | ||
Debt Instrument [Line Items] | ||
Interest Rate | 1.95% | |
Long-term debt | $ 498 | 498 |
Unsecured Debt | Senior Unsecured Notes Due in September 2022 | ||
Debt Instrument [Line Items] | ||
Interest Rate | 3.25% | |
Long-term debt | $ 997 | 997 |
Unsecured Debt | Senior Unsecured Notes Due in September 2023 | ||
Debt Instrument [Line Items] | ||
Interest Rate | 2.50% | |
Long-term debt | $ 746 | 746 |
Unsecured Debt | Senior Unsecured Notes Due in April 2024 | ||
Debt Instrument [Line Items] | ||
Interest Rate | 3.70% | |
Long-term debt | $ 1,744 | 1,744 |
Unsecured Debt | Senior Unsecured Notes Due in February 2025 | ||
Debt Instrument [Line Items] | ||
Interest Rate | 3.50% | |
Long-term debt | $ 1,745 | 1,745 |
Unsecured Debt | Senior Unsecured Notes Due in March 2026 | ||
Debt Instrument [Line Items] | ||
Interest Rate | 3.65% | |
Long-term debt | $ 2,732 | 2,731 |
Unsecured Debt | Senior Unsecured Notes Due in March 2027 | ||
Debt Instrument [Line Items] | ||
Interest Rate | 2.95% | |
Long-term debt | $ 1,245 | 1,245 |
Unsecured Debt | Senior Unsecured Notes Due in September 2035 | ||
Debt Instrument [Line Items] | ||
Interest Rate | 4.60% | |
Long-term debt | $ 990 | 990 |
Unsecured Debt | Senior Unsecured Notes Due in September 2036 | ||
Debt Instrument [Line Items] | ||
Interest Rate | 4.00% | |
Long-term debt | $ 740 | 740 |
Unsecured Debt | Senior Unsecured Notes Due in December 2041 | ||
Debt Instrument [Line Items] | ||
Interest Rate | 5.65% | |
Long-term debt | $ 995 | 995 |
Unsecured Debt | Senior Unsecured Notes Due in April 2044 | ||
Debt Instrument [Line Items] | ||
Interest Rate | 4.80% | |
Long-term debt | $ 1,734 | 1,734 |
Unsecured Debt | Senior Unsecured Notes Due in February 2045 | ||
Debt Instrument [Line Items] | ||
Interest Rate | 4.50% | |
Long-term debt | $ 1,731 | 1,730 |
Unsecured Debt | Senior Unsecured Notes Due in March 2046 | ||
Debt Instrument [Line Items] | ||
Interest Rate | 4.75% | |
Long-term debt | $ 2,217 | 2,216 |
Unsecured Debt | Senior Unsecured Notes Due in March 2047 | ||
Debt Instrument [Line Items] | ||
Interest Rate | 4.15% | |
Long-term debt | $ 1,725 | $ 1,724 |
London Interbank Offered Rate (LIBOR) | 2017 Senior Unsecured Notes Due in September 2019 with Floating Rate | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Basis Spread on Variable Rate | 0.25% | |
London Interbank Offered Rate (LIBOR) | 2017 Senior Unsecured Notes Due in March 2019 | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Basis Spread on Variable Rate | 0.22% |
Debt and Credit Facilities Addi
Debt and Credit Facilities Additional Information (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | |
Apr. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | |
Term Loan Facilities | |||
Debt Instrument [Line Items] | |||
Line of Credit Facility, Maximum Borrowing Capacity | $ 2,500 | ||
Amount outstanding | 0 | $ 0 | |
Senior Unsecured Note Issued September 2017 [Member] | Unsecured Debt | |||
Debt Instrument [Line Items] | |||
Repayments of Unsecured Debt | $ 750 | ||
Subsequent Event | Senior Unsecured Note Issued September 2014 [Member] | Unsecured Debt | |||
Debt Instrument [Line Items] | |||
Repayments of Unsecured Debt | $ 500 |
Leases Narrative (Details)
Leases Narrative (Details) $ in Millions | 3 Months Ended |
Mar. 31, 2019USD ($) | |
Leases [Abstract] | |
Lease term extension | 15 years |
Termination period | 1 |
Operating lease expense | $ 36 |
Leases Balance Sheet Location D
Leases Balance Sheet Location Detail (Details) $ in Millions | Mar. 31, 2019USD ($) |
Leases [Abstract] | |
Right-of-use assets, net | $ 455 |
Lease liabilities - current | 75 |
Lease liabilities - noncurrent | $ 429 |
Weighted average remaining lease term | 9 years 6 months |
Weighted average discount rate | 3.61% |
Leases Supplemental Information
Leases Supplemental Information Related to Leases (Details) $ in Millions | 3 Months Ended |
Mar. 31, 2019USD ($) | |
Leases [Abstract] | |
Cash paid for amounts included in the measurement of lease liabilities | $ 18 |
Right-of-use assets obtained in exchange for lease liabilities | $ 30 |
Leases Summary of Operating Lea
Leases Summary of Operating Lease Liabilities Maturity (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Operating Leases, Summary of Aggregate Future Lease Payments After Adoption of 842 | ||
2019 (remaining nine months) | $ 69 | |
2020 | 84 | |
2021 | 72 | |
2022 | 65 | |
2023 | 57 | |
Thereafter | 257 | |
Total undiscounted lease payments | 604 | |
Less: imputed interest | (100) | |
Total discounted lease payments | $ 504 | |
Operating Leases, Summary of Aggregate Future Lease Payments Before Adoption of 842 | ||
2019 | $ 89 | |
2020 | 78 | |
2021 | 66 | |
2022 | 60 | |
2023 | 52 | |
Thereafter | 229 | |
Total minimum lease payments | $ 574 |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | ||||
Dec. 31, 2016 | Mar. 31, 2016 | Mar. 31, 2018 | Sep. 30, 2016 | Mar. 31, 2019 | Dec. 31, 2018 | |
Loss Contingencies [Line Items] | ||||||
Litigation accrual | $ 0 | $ 0 | ||||
Indenix [Member] | ||||||
Loss Contingencies [Line Items] | ||||||
Damages awarded | $ 2,540 | |||||
Motion invalidated past damages, amount | $ 2,540 | |||||
Merck '499 and '712 patents | ||||||
Loss Contingencies [Line Items] | ||||||
Damages awarded | $ 200 | |||||
Damages awarded but dismissed, amount | $ 200 |
Stockholders' Equity Summary of
Stockholders' Equity Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | Jan. 01, 2018 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||
Beginning Balance | $ 21,534 | $ 20,501 | |
Net current period other comprehensive income (loss) | 50 | (42) | |
Ending Balance | 22,091 | 20,651 | |
Foreign Currency Translation | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||
Beginning Balance | 47 | 85 | |
Reclassifications to retained earnings as a result of the adoption of new accounting standards | $ 0 | ||
Balance at January 1, 2018 | 85 | ||
Net unrealized gain (loss) | 21 | 7 | |
Reclassifications to net income | 0 | 0 | |
Net current period other comprehensive income (loss) | 21 | 7 | |
Ending Balance | 68 | 92 | |
Unrealized Gains and Losses on Available-for-Sale Securities | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||
Beginning Balance | (52) | 194 | |
Balance at January 1, 2018 | (99) | ||
Net unrealized gain (loss) | 30 | (36) | |
Reclassifications to net income | 0 | 0 | |
Net current period other comprehensive income (loss) | 30 | (36) | |
Ending Balance | (22) | (135) | |
Unrealized Gains and Losses on Cash Flow Hedges | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||
Beginning Balance | 85 | (114) | |
Reclassifications to retained earnings as a result of the adoption of new accounting standards | 0 | ||
Balance at January 1, 2018 | (114) | ||
Net unrealized gain (loss) | 28 | (61) | |
Reclassifications to net income | (29) | 48 | |
Net current period other comprehensive income (loss) | (1) | (13) | |
Ending Balance | 84 | (127) | |
AOCI Attributable to Parent | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||
Beginning Balance | 80 | 165 | |
Reclassifications to retained earnings as a result of the adoption of new accounting standards | (293) | ||
Balance at January 1, 2018 | $ (128) | ||
Net unrealized gain (loss) | 79 | (90) | |
Reclassifications to net income | (29) | 48 | |
Net current period other comprehensive income (loss) | 50 | (42) | |
Ending Balance | $ 130 | $ (170) |
Stockholders' Equity Stock Repu
Stockholders' Equity Stock Repurchase Program (Details) - 2016 Stock Repurchase Program - USD ($) shares in Millions, $ in Millions | 3 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | Jan. 28, 2016 | |
Equity, Class of Treasury Stock [Line Items] | |||
Authorized amount | $ 12,000 | ||
Repurchases of common stock (in shares) | 12 | 13 | |
Repurchases of common stock, amount | $ 834 | $ 1,000 | |
Remaining authorized repurchase amount | $ 4,300 |
Net Income Per Share Attribut_3
Net Income Per Share Attributable to Gilead Common Stockholders - Additional Information (Details) - shares shares in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Additional Information [Abstract] | ||
Antidilutive securities excluded from earnings per share computation (in shares) | 16 | 12 |
Net Income Per Share Attribut_4
Net Income Per Share Attributable to Gilead Common Stockholders - Schedule of the Calculation of Basic and Diluted EPS (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Earnings Per Share [Abstract] | ||
Net income attributable to Gilead | $ 1,975 | $ 1,538 |
Shares used in per share calculation - basic (in shares) | 1,276 | 1,307 |
Dilutive effect of stock options and equivalents (in shares) | 7 | 13 |
Shares used in per share calculation - diluted (in shares) | 1,283 | 1,320 |
Net income per share attributable to Gilead common stockholders - basic (usd per share) | $ 1.55 | $ 1.18 |
Net income per share attributable to Gilead common stockholders - diluted (usd per share) | $ 1.54 | $ 1.17 |
Segment Information - Summary o
Segment Information - Summary of Revenue by Major Customers (Details) - segment | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Segment Reporting [Abstract] | ||
Number of operating segments | 1 | |
Customer Concentration Risk | Sales Revenue, Net | AmerisourceBergen Corp. | ||
Revenue, Major Customer [Line Items] | ||
Percentage of total revenues | 21.00% | 21.00% |
Customer Concentration Risk | Sales Revenue, Net | Cardinal Health, Inc. | ||
Revenue, Major Customer [Line Items] | ||
Percentage of total revenues | 20.00% | 21.00% |
Customer Concentration Risk | Sales Revenue, Net | McKesson Corp. | ||
Revenue, Major Customer [Line Items] | ||
Percentage of total revenues | 20.00% | 20.00% |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Income Tax Disclosure [Abstract] | ||
Effective income tax rate | 16.30% | 24.30% |
Tax Adjustments, Settlements, and Unusual Provisions | $ 49 | |
Decrease in Unrecognized Tax Benefits/Tax Expenses As a Result of Settlements with Taxing Authoritiess | $ 119 |
Uncategorized Items - gild-2019
Label | Element | Value |
Accounting Standards Update 2016-02 [Member] | ||
Cumulative Effect of New Accounting Principle in Period of Adoption | us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption | $ 8,000,000 |
Accounting Standards Update 2016-02 [Member] | Retained Earnings [Member] | ||
Cumulative Effect of New Accounting Principle in Period of Adoption | us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption | 8,000,000 |
Accounting Standards Update 2016-01 [Member] | ||
Cumulative Effect of New Accounting Principle in Period of Adoption | us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption | 190,000,000 |
Accounting Standards Update 2016-01 [Member] | AOCI Attributable to Parent [Member] | ||
Cumulative Effect of New Accounting Principle in Period of Adoption | us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption | (293,000,000) |
Accounting Standards Update 2016-01 [Member] | Retained Earnings [Member] | ||
Cumulative Effect of New Accounting Principle in Period of Adoption | us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption | $ 483,000,000 |